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 Nanotechnology can be defined as the science and engineering involved in the 
design, synthesis, characterization and application of materials and devices whose 
smallest functional organization in at least one dimension is on the nanometer scale 
(one-billionth of a meter). In the past few years nanotechnology has grown by leaps 
and bounds, and this multidisciplinary scientific field is undergoing explosive 
development . It can prove to be a boon for human health care, because nano science 
and nanotechnologies have a huge potential to bring benefits in areas as diverse as 
drug development, water decontamination, information and communication 
technologies, and the production of stronger, lighter materials. Human health-care 
nanotechnology research can definitely result in immense health benefits. The genesis 
of nanotechnology can be traced to the promise of revolutionary advances across 
medicine, communications, genomics, and robotics. A complete list of the potential 
applications of nanotechnology is too vast and diverse to discuss in detail, but without 
doubt, one of the greatest values of nanotechnology will be in the development of new 
and effective medical treatments. This review focuses on the potential of 
nanotechnology in medicine, including the development of nanoparticles for drug and 
gene delivery and diagnostics. These technologies will extend the limits of current 
molecular diagnostics and permit accurate diagnosis as well as the development of 
personalized medicine. 
The prefix “nano” derives from the Greek word for “dwarf”. One nanometer (nm) is 
equal to one-billionth of a meter, or about the width of  6 carbon atoms or 10 water 
molecules. (Sahoo S K et al., 2007). 
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Types: 
i. Nanoscience:  
Nanoscience refers to scientific activity that occurs with  in the range of  1-
100 nanometers and is usually aimed at constructing devices with atomic 
precision. (Christine M shea et al., 2005). 
ii.  Nanomedicine: 
Nanomedicine defined as the monitoring, repair, construction, and control 
of human biological systems at the molecular level, using engineered nano 
devices and nano structures.  It can also be regarded as another 
implementation of nanotechnology in the field of medical sciences and 
diagnostics. One of the most important issues is the proper distribution of 
drugs and other therapeuctic agents within the patient’s body. 
(Sahoo S K et al., 2007).   
iii. Nanotechnology: 
Nanotechnology is the application of nanoscientific developments toward 
some commercial objective.  It is enabled by advances in and the 
convergence of the fields of physics, chemistry, biology, materials science, 
and engineering principles and tools, and encompasses the entire domain 
of the building, integration and application of nanoscale structures in to 
larger material components, systems and architectures. 
(Christine M shea et al., 2005). 
Nanotechnology in drug delivery: 
 The development of delivery systems for small molecules, proteins and DNA 
has been impacted to an enormous degree over the past decade by nanotechnology, 
and has led to the development of entirely new and somewhat unpredicted fields. For 
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the pharmaceutical industry, novel drug delivery technologies represent a strategic 
tool for expanding drug markets. The technology can address issues associated with 
current pharmaceuticals such as extending product life (line extension), or can add to 
their performance and acceptability, either by increasing efficacy or improving safety 
and patient compliance. In addition, the newer drugs developed with the help of 
computational chemistry using the knowledge gained from the human genome project 
require drug delivery systems for their effective use. This technology permits the 
delivery of drugs that are highly water-insoluble or unstable in the biological 
environment. It is expected that novel drug delivery systems can make a significant 
contribution to global pharmaceutical sales. This is illustrated by the fact that 
approximately 13% of the current global pharmaceutical market is accounted for by 
sales of products incorporating a drug delivery system. In recent years, many new 
pharmaceutical companies have been established that can provide expertise in 
innovative delivery technology. Also, many established pharmaceutical industries are 
gearing-up their efforts towards developing more effective and performance-based 
new drug delivery systems. The demand for drug delivery systems in the United 
States alone is expected to grow nearly 9% annually to more than US$82 billion by 
2007. (Sanjeeb K Sahoo et al., 2003). 
Significance of Drug Delivery and Targeting: 
              Although opportunities to develop nanotechnology-based efficient drug 
delivery systems extend into all therapeutic classes of pharmaceuticals, the 
development of effective treatment modalities for the respiratory, central nervous 
system and cardiovascular disorders remains a financially and therapeutically 
significant need. Many therapeutic agents have not been successful because of their 
limited ability to reach to the target tissue. In addition, the faster growth opportunities 
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are expected in developing delivery systems for anti-cancer agents, hormones and 
vaccines because of safety and efficacy shortcomings in their conventional 
administration modalities. For example, in cancer chemotherapy, cytostatic drugs 
damage both malignant and normal cells alike. Thus, a drug delivery strategy that 
selectively targets the malignant tumor is very much needed. Additional problems 
include drug instability in the biological milieu and premature drug loss through rapid 
clearance and metabolism. Similarly, high protein binding of certain drugs such as 
protease inhibitors limits their diffusion to the brain and other organs. However, 
nanotechnology for drug delivery applications may not  be suitable for all drugs, 
especially those drugs that are less potent because the higher dose of the drug would 
make the drug delivery system much larger, which would be difficult to administer.  
(Sanjeeb K Sahoo et al., 2003). 
Types of collodal nanocarriers 
1. Polymeric nanoparticles: 
 Polymeric nanoparticles (PNPs) are prepared from a synthetic polymeric block 
to increase the circulation half-life and to reduce phagocytic uptake and inactivation 
of the therapeutic moiety and can be used to deliver and target therapeutic agents. 
They are formulated by incorporation of biodegradable polymers to maximize tissue 
compatibility and minimize cytotoxicity. Polymers approved by the U.S. Food and 
Drug Administration (FDA) for administration in human beings are polylactic acid 
(PLA), poly(glycolic acid) (PGA), PLGA, poly-ecaprolactone, and poly(methyl 
methacrylate). For example, PLA and PLGA can easily be hydrolyzed into individual 
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3. Magnetic nanoparticles: 
 Magnetically targeted nanoparticulate drug delivery systems involve binding 
of drug with magnetic nanoparticles, such as oxidized iron (Fe) or magnetite. By 
virtue of their controllable sizes (ranging from 10 to 100 nm) and capacity of 
delivering the drug or radionucleotide in the vicinity of a target site, they provide a 
good scope in drug delivery. For biomedical applications, magnetic carriers must be 
water based, biocompatible, nontoxic, and nonimmunogenic. Various magnetic 
carriers, which receive external magnetic field, include nickel, cobalt, iron, and 
magnetite. Iron oxide is most commonly used because of its biodegradable nature, 
biocompatibility, super paramagnetic effects, and capacity to serve as a contrast agent 
in magnetic resonance imaging (MRI). Iron oxide particles are phagocytosed or 
endocytosed by the kupffer cell in the RES of liver, spleen, lymph, and bone marrow. 
Once compartmentalized within the lysosomes of RES cells, they are broken down 
into ferritin and/or hemosiderin, which are antiferromagnetic forms of iron. The 
concentration of carriers at any specific location can be manipulated by calculation of 
capillary flow rate, vascular permeability, and hydrodynamic condition of the 
individual. For therapeutic effect, magnetic nanoparticles are injected into the 
bloodstream, and a high gradient magnetic field is generated outside the body so as to 
pull them out of suspension and deliver the drug to a localized disease site. Coating 
with dextran or PEG improves its water dispersibility. Iron oxide magnetic 
nanoparticles, coated with oleic acid, were stabilized by pluronic F-127 to form a 
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Applications of nanotechnology 
a) Nanotechnology in drug delivery 
 Nanotechnologies in medicine are especially promising, and areas such as 
disease diagnosis, drug delivery targeted at specific sites in the body, and molecular 
imaging are being intensively investigated and some products undergoing clinical 
trials. Nanotechnology is relatively new, and although the full scope of contributions 
of these technological advances in the field of human health care remains unexplored, 
recent advances suggest that nanotechnology will have a profound impact on disease 
prevention, diagnosis, and treatment. 
 Drug solubility and cell permeability issues are also common with small 
molecules and biologically active compounds. Nanotechnology- based delivery 
systems could mitigate these problems by combining tissue- or organ-specific 
targeting with therapeutic action. Multifunctional nanodelivery systems could also 
combine targeting, diagnostic, and therapeutic actions. 
 The most important clinical applications of nanotechnology are likely to be in 
pharmaceutical development. There are already an astonishing number of emerging 
applications. These applications either take advantage of the unique properties of 
nanoparticles as drugs or components of drugs per se or are designed for new 
approaches to controlled release, drug targeting, and salvage of drugs with low 
bioavailability. 
 Drug bioavailability is a related problem with potential nanotechnology 
solutions. Nanotechnology is opening new therapeutic opportunities for many agents 
that cannot be used effectively as conventional oral formulations because of their poor 
bioavailability. In some cases, reformulation of a drug with smaller particle size may 
improve oral bioavailability. Nanoparticles formulations provide protection for agents 
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susceptible to degradation or denaturation in regions of harsh pH, and also prolong the 
duration of exposure of a drug by increasing retention of the formulation through  
bioadhesion. 
 Another broad application of nanotechnology is the delivery of antigens for 
vaccination. Mucosal immunity is extremely important in disease prevention but 
continues to be limited by both degradation of the vaccine and limited uptake. Recent 
advances in encapsulation and development of suitable animal models have 
demonstrated that microparticles and nanoparticles are capable of enhancing 
immunization.(S K Sahoo et al., 2007) 
 Nanobots are robots that carry out a very specific function and are just several 
nanometers wide. They can be used very effectively for drug delivery. Normally, 
drugs work through the entire body before they reach the disease affected area. Using 
nanotechnology, the drug can be targeted to a precise location which would make the 
drug much more effective and reduce the chances of possible side-effects.(Debjit 
bhowmik et al., 2009). 
Diagnosis and Imaging: 
 Nanobiotech scientists have successfully produced microchips that are coated 
with human molecules. The chip is designed to emit an electrical impulse signal when 
the molecules detect signs of a disease. Special sensor nanobots can be inserted into 
the blood under the skin where they check blood contents and warn of any possible 
diseases. They can also be used to monitor the sugar level in the blood. Advantages of 
using such nanobots are that they are very cheap to produce and easily.(Debjit 
bhowmik et al., 2009). 
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Preventing diseases: 
a. heart-attack prevention: 
 Nanobots can also be used to prevent heart-attacks. Heart-attacks are caused 
by fat deposits blocking the blood vessels. Nanobots can be made for removing these 
fat deposits (Harry, 2005). The following figure shows nanobots removing the yellow 
fat deposits on the inner side of blood vessels. 
b. frying tumors: 
 Nanomaterials have also been investigated into treating cancer. The therapy is 
based on “cooking tumors” principle. Iron nanoparticles are taken as oral pills and 
they attach to the tumor. Then a magnetic field is applied and this causes the 
nanoparticles to heat up and literally cook the tumors from inside out. 
c. Tissue Reconstruction: 
 Nanoparticles can be designed with a structure very similar to the bone 
structure. An ultrasound is performed on existing bone structures and then bonelike 
nanoparticles are created using the results of the ultrasound. The bone like 
nanoparticles are inserted into the body in a paste form. When they arrive at the 
fractured bone, they assemble themselves to form an ordered structure which later 
becomes part of the bone. Another key application for nanoparticles is the treatment 
of injured nerves. Samuel Stupp and John Kessler at Northwestern University in 
Chicago have made tiny rod like nano fibers called amphiphiles. They are capped 
with amino acids and are known to spur the growth of neurons and prevent scar tissue 
formation. Experiments have shown that rat and mice with spinal injuries recovered 
when treated with these nano-fibers.(Debjit bhowmik et al., 2009). 
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Nanotechnology in gene delivery: 
 nanotechnological tools in human gene therapy has been reviewed widely by  
davis, who described nonviral vectors based on nanoparticles (usually 50-500 nm in 
size) that were already tested to transport plasmid DNA. He emphasized that 
nanotechnology in gene therapy would be applied to replace the currently used viral 
vectors by potentially less immunogenic nanosize gene carriers. So delivery of 
repaired genes or the replacement of incorrect genes are fields in which nanoscale 
objects could be introduced successfully. 
Nanotechnology in dental care: 
 Nanotechnology will have future medical applications in the field of 
nanodentistry. Nanodentistry will make it possible to maintain near-perfect oral health 
through the use of nanomaterials, biotechnology, and nanorobotics. 
 A colloidal suspension containing millions of active analgesic dental 
nanorobotic particles could be instilled on the patient’s gingivae. These nanorobots, 
after contacting the surface of the crown or mucosa, reach the dentin by migrating 
into the gingival sulcus and pass painlessly to the target site. On reaching the dentin, 
the nanorobots enter dentinal tubule holes that are 1 to 4 Am in diameter  and proceed 
toward the pulp, guided by a combination of chemical gradients, temperature 
differentials, and even positional navigation, all under the control of the onboard 
nanocomputer as directed by the dentist.  
Nanotechnology in orthopedic applications: 
 Biomaterials proposed as ideal scaffolds for cell growth should be 
biocompatible, osteoinductive, osteoconductive, integrative, porous, and mechanically 
compatible with native bone to fulfill their desired role as bone implants and 
substitutes. 
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 Nanostructure materials with sizes 1 to 100 nm can act as new and effective 
constituents of bone materials, because bone is also made up of nanosized organic and 
mineral phases. 
 Nanomaterials, nanopolymers, carbon nanofibers, nanotubes, and 
nanocomposites of ceramics will also lead to more efficient deposition of calcium 
containing minerals on the implants. 
Nanotechnology as a risk to human health: 
 Nanomaterials can enter the human body through several ports. Accidental or 
involuntary contact during production or use is most likely to occur via the lungs, 
from which a rapid translocation is possible to other vital organs through the 
bloodstream. On the cellular level, an ability to act as a gene vector has been 
demonstrated for nanoparticles. Carbon black nanoparticles have been implicated in 
interfering with cell signaling. There is work that demonstrates uses of DNA for the 
size separation of carbon nanotubes. The DNA strand just wraps around it if the tube 
diameter is right. Though excellent for the purposes of separation, this tendency raises 
some concerns over the consequences of carbon nanotubes entering the human body. 
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CHAPTER II 
REVIEW ON POLYMERIC NANOPARTICLES 
Introduction: 
  The field of polymer nanoparticles is quickly expanding and playing a 
pivotal role in a wide spectrum of areas ranging from electronics to photonics, 
conducting materials to sensors, medicine to biotechnology, pollution control to 
environmental technology, and so forth, during the past decades. 
 Polymeric nanoparticulate systems from biodegradable and biocompatible 
polymers are interesting options for controlled drug delivery and drug targeting.  
Polymer nanoparticles are solid colloidal particles with diameter ranging from 1 to 
1000nm.  They have been investigated especially in drug delivery and drug targeting 
owing to their particle size and long circulation in the blood.  They consist of 
macromolecular materials and can be used therapeutically as adjuvant in vaccines or 
drug carriers in which the active ingredient is dissolved, entrapped, encapsulated, 
adsorbed or chemically attached.  
 Nanoparticles have been widely used in biomedical applications due to their 
specific physical and chemical properties which alter the normal biological activity, as 
compared to bulk materials. Science-based definition must be developed by several 
national and international standardization bodies, as well as organizations and 
authorities in order to have a definition that is broadly applicable to regulatory 
legislations. 
 Polymeric nanomaterials offer a promising solution by encapsulating 
chemotherapy drugs, and have been shown to reduce toxicity by providing a 
protective housing for the drug that limits its interaction with healthy cells. As a 
result, the pharmacokinetic properties of the drug are based on the pharmacokinetic 
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properties of the particle, as long as the drug can stay entrapped with the carrier until 
release is desired. The potential benefits of such delivery devices also include 
controlled and long-term release rates, prolonged bioactivity, reduced side effects, 
increased patient compliance due to decreased administration frequency, and the 
ability to codeliver multiple drugs with synergistic effects to the same site.  
 Current research has thus focused on advancing these polymer vehicles with 
“smart” technologies that are responsive to environmental stimuli. These can be 
separated into two categories: (1) site-targeting, where particles actively search for 
and attach themselves to specific and diseased cells by the use of molecules such as 
ligands, antibodies, and aptamers; (2) site-triggering, where chemical or physical 
changes in the environment trigger the rapid release of the drug payload. This review 
focuses on a few selected “smart” technologies in each category: ligand and aptamer 
site-targeting particles, and pH and temperature-responsive particles. (Kurt E 
Geckeler et al., 2011 Erik brewer et al., 2011 Aura Ileana Moreno Vega et al.,2012). 
Advantages of polymeric nanoparticles: 
a) Increases the stability of any volatile pharmaceutical agents, easily and 
cheaply fabricated in large quantities by a multitude of methods.  
b) They offer a significant improvement over traditional oral and intravenous 
methods of administration in terms of efficiency and effectiveness.  
c) Delivers a higher concentration of pharmaceutical agent to a desired location.  
d) The choice of polymer and the ability to modify drug release from polymeric 
nanoparticles have made them ideal candidates for cancer therapy, delivery of 
vaccines, contraceptives and delivery of targeted antibiotics.  
e) Polymeric nanoparticles can be easily incorporated into other activities related 
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 Sodium alginate  
 Albumin  
There are many synthetic polymers like  
 Polylactides(PLA)  
 Polyglycolides(PGA)  
 Poly(lactide co-glycolides) (PLGA)  
 Polyanhydrides  
 Polyorthoesters  
 Polycyanoacrylates  
 Polycaprolactone  
 Poly glutamic acid  
 Poly malic acid  
 Poly(N-vinyl pyrrolidone)  
 Poly(methyl methacrylate)  
 Poly(vinyl alcohol  
 Poly(acrylic acid)  
 Poly acrylamide  
 Poly(ethylene glycol)  
 Poly(methacrylic acid)              
(Hemant K.S.Yadav et al., 2012) 
 Preparation techniques for polymer nanoparticles: 
 Polymeric nanoparticles can be conveniently prepared either from preformed 
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interfacial tension between the two phases, which increases the surface area and leads 
to the formation of small droplets of organic solvent. 
  Nanoprecipitation system consists of three basic components: the polymer 
(synthetic, semi synthetic or natural), the polymer solvent and the non-solvent of the 
polymer. Organic solvent (i.e., ethanol, acetone, hexane, methylene chloride or 
dioxane) which is miscible in water and easy to remove by evaporation is choosen as 
polymer solvent.  
 Due to this reason, acetone is the most frequently employed polymer solvent 
in this method. Sometimes, it consists of binary solvent blends, acetone with small 
amount of water, blends of acetone with ethanol  and methanol. On the other hand, the 
non-solvent phase consisting of a non-solvent or a mixture of non-solvents is 
supplemented with one or more naturally occurring or synthetic surfactants.  
 The key variables determining the success of the method and affecting the 
physicochemical properties of polymeric nanoparicles are those associated with the 
conditions of adding the organic phase to the aqueous phase, such as organic phase 
injection rate, aqueous phase agitation rate, the method of organic phase addition and 
the organic phase to aqueous phase ratio.  
 Likewise, polymeric nanoparticles characteristics are influenced by the nature 
and concentration of their components. Although, a surfactant is not required to 
ensure the formation of polymeric nanoparticles by nanoprecipitation, the particle size 
is influenced by the surfactant nature and concentration.  
 Moreover, the addition of surfactants helps to preserve the nanoparticle 
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 Supercritical fluid technology: 
 As may be noted, the methods in the preceding subsections involve organic 
solvents, and the need to develop environmentally safer methods for the production of 
polymeric nanoparticles has motivated research on the utility of supercritical fluids as 
more environmental friendly solvents, with the potential to produce polymeric 
nanoparticles with high purity and without any trace of organic solvent. Supercritical 
fluid and dense gas technology are expected to offer an interesting and effective 
technique of particle production, avoiding most of the drawbacks of the traditional 
methods. Indeed, examples have been published on pharmaceutical particle formation, 
formulation, and control with a supercritical fluid and dense gas. 
Two principal processes have been developed for the production of nanoparticles 
using supercritical fluids: 
 1. Rapid expansion of supercritical solution (RESS) 
 2. Rapid expansion of supercritical solution into liquid solvent (RESOLV) 
1. Rapid expansion of supercritical solution (RESS) : 
 In traditional RESS, the solute is dissolved in a supercritical fluid to form a 
solution, followed by the rapid expansion of the solution across an orifice or a 
capillary nozzle into ambient air.  
 The high degree of supersaturation, accompanied by the rapid pressure 
reduction in the expansion, results in homogenous nucleation and, thereby, the 
formation of well-dispersed particles.  
 Results from mechanistic studies of different model solutes for the RESS 
process indicate that both nanometer- and micrometer-sized particles are present in 
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Physicochemical characteristics of polymeric nanoparticles: 
 Particle size   –  Photon correlation spectroscopy,    
       Transmission electron microscopy,   
                  Scanning electron microscopy,         
       Scanned probed microscope,    
       Fraunhofer diffraction,     
       Freeze fracture electron microscopy. 
 Molecular weight  -  Gel chromatography 
 Density   –  Helium compression pycnometry 
 Crystallinity   – X-ray diffraction, Differential scanning   
       calorimetry 
 Surface charge   – Zeta potential measurement,    
       Electrophoresis,         
       Laser droplet anemometry,                             
       Amplitude weighed phase structure determination. 
 Hydrophobicity   -  Hydrophobic interaction chromatography,  
       Contact angle measurement,    
        Rose Bengal binding. 
 Surface properties   - Static secondary-ion mass spectroscopy 
 Surface element analysis - X-ray photon spectroscopy,    
          Molecular magnetic resonance,    
          Fourier transform infrared spectroscopy. 
Drug loading : 
 Incorporation method : Incorporating at the time of nanoparticles  
     production. 
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 Incubation method : Adsorbing the drug after the formation of  
     nanoparticles by incubating the carrier with the 
     concentrated drug solution. 
Drug release and release kinetics: 
 Release from the surface of particles 
 Diffusion through the swollen rubbery matrix  
 Release due to erosion 
Administration of polymeric nanoparticles: 
 Intravenous administration 
 Passive targeting  
 Active targeting 
 Subcutaneous and intramuscular injection  
 Oral administration 
 Ophthalmic application 
 Nanoparticles and targeted drug delivery 
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Applications of nanoparticles in drug delivery 
S.No Application Material used Purpose 









uptake of antitumour 
agents, improved in 
vitro and invivo 
stability. 
2 Intracellular targeting  Poly (alkyl cyanoacrylate) 
polyesters nanoparticles with 





3 Prolonged systemic 
circulation 
Polyesters with adsorbed poly 
ethylene glycols or pluronics 
Prolonged systemic 




4 Vaccine adjuvant Poly (methyl methacrylate) 
nanoparticles with vaccines 




5 Peroral absorption Poly (methyl methacrylate) 




protection from GIT 
enzymes 
6 Ocular delivery Poly (alkyl cyanoacrylate) 
nanoparticles with steroids, 
Improved retention 
of drug/ reduced 
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anti- inflammatory agents, anti 
bacterial agents for glaucoma 
wash out 










Alginate nanoparticles, poly 
(D,L-lactic acid ) nanoparticles 
Enhanced delivery of 
oligonucleotides 
9 Other applications Poly (alkyl cyanoacrylate) 
nanoparticles with peptides, 
poly ( alkyl cyanoacrylate) 
nanoparticles, Nanoparticles 
with adsorbed enzymes 
Crosses BBB, 
Improved absorption 
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CHAPTER  III 
LITERATURE REVIEW 
Hadi Valizadeh et al., 2013, prepared Vancomycin loaded PLGA nanoparticles 
by double emulsion solvent evaporation method.  The nanoparticles were 
characterized for their micrometritic and crystallographic properties, particle size, 
zeta potential, drug loading and release.  Intestinal permeability of vancomycin- 
PLGA nanoparticles was determined in different concentrations using SPIP 
technique in rats.  Particle sizes were between 450nm and 466nm for different 
compositions of vancomycin-PLGA nanoparticles.  Entrapment efficiency ranged 
between 38.38% and 78.6% with negative zeta potential.  The FT-IR, XRPD and 
DSC results ruled out any chemical interaction between the drug and PLGA.  
Effective intestinal permeability values of vancomycin nanoparticles in 
concentrations of 200, 300 and 400µg/ml were significantly higher than that of 
solutions at the same concentrations.  The PLGA nanoparticles could provide a 
delivery system for vancomycin with enhanced intestinal permeability. 
Ping Yao et al., 2013,  prepared Doxorubicin loaded Biocompatible and 
biodegradable nanoparticles by BSA–dextran–folic acid conjugate via a pH 
adjustment and heating process. The BSA–dextran–folic acid conjugate was 
produced by an esterification reaction between folic acid and dextran and then the 
maillard reaction between the modified dextran and BSA. The nanoparticles have 
a size about 90nm and excellent dispersibility at pH 7.4 aqueous solution. The 
doxorubicin loading efficiency and loading amount of the nanoparticles are larger 
than 90% and 14%, respectively. The antitumor activity and toxicity of the 
nanoparticles were evaluated through murine ascites hepatoma H22 tumor-bearing 
mice. The nanoparticles allow the administration of the doxorubicin with higher 
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dose. At doxorubicin dose of 10 mg/kg, the nanoparticles can achieve 88.9% of 
the tumor inhibition rate that is the same as the free doxorubicin at the dose of 5 
mg/kg. Importantly, the nanoparticles can decrease the toxicity of doxorubicin that 
results in a significant increase of the average life time in comparison with the free 
doxorubicin as well as the nanoparticles without folic acid. 
Aravind Gulbake et al., 2013, developed Mesalazine (MSZ) loaded Chitosan 
nanoparticles (CH-NPs)  by ionotropic gelation method. Encapsulated in Eudragit 
S100 coated pellets for site specific delivery to ulcerative colitis (UC). The CH-
NPs were characterized for size and structure using Malvern zetasizer and 
transmission electron microscope (TEM). The average size of the uncoated CH-
NPs was about 157.3±7.1 nm, with the zeta potential of 32.2±2.1 mV, suitable for 
uptake through the colonic mucosa due to their nano size range and mucoadhesive 
properties. The in vitro drug release from developed formulations was 
investigated using a USP dissolution rate test paddle-type apparatus in different 
simulated gastrointestinal tract fluids. The coated formulation shows no release, 
and uncoated CH-NPs showed 4.98±0.24 % of mesalazine in SGF pH 1.2. This 
suggests that the release of drugs from coated nanoparticles was pH-responsive. 
At the end of 24hours 69.24±3.4% and 45.26±2.4% of mesalazine was released 
from CH-NPs and EC-CH-NPs. The mesalazine and pellets of CH-NPs and EC-
CH-NPs bearing mesalazine were separately administered orally at the dose of 50 
mg/kg body weight to albino rats and evaluated for antiulcerogenic activity. 
Krishna Sailaja A et al., 2013, prepared Nimesulide loaded cellulose acetate 
hydrogen phthalate nanoparticles by salting out technique. Nanoparticles were 
evaluated for particle size, zetapotential and particle size distribution. Size of the 
particle was measured by Scanning electron microscope. Surface charge and 
CHAPTER III                                                                         LITERATURE REVIEW	
 
Felodipine Polymeric Nanoparticles Reg.No.261211303           Page 39 
 
stability of the resultant nanoparticles was determined by Zetasizer.  Particle size 
distribution was determined by Photon Correlation Spectroscopy (PCS) with a 
Malvern Zetasizer Nano-ZS. The cellulose acetate hydrogen phthalate 
concentration and nimesulide concentration was varied from 5mg/ml to 10 mg/ml. 
The effect of drug and polymer concentrations on nanoparticle size, shape, 
particle size distribution was studied. Increased drug concentration has no impact 
on the particle size. The size of the particle was found to be decreased with 
increased polymer concentration. Increased polymer concentration has resulted in 
uniform particle size distribution. Higher the polymer concentrations and lower 
the drug concentrations resulted in uniform particle size distribution. 
Vyjayanthimala T et al., 2013,  formulated Stavudine loaded chitosan and 
eudragit nanoparticles by emulsion droplet coalescence method. The nanoparticles 
were evaluated for morphology, loading efficiency and in-vitro release. The 
particle shape and morphology of the prepared stavudine nanoparticles were 
determined by SEM analysis. The amount of Stavudine entrapment in the 
nanoparticles was calculated by the difference between the total amount of drug 
added to the nanoparticle and the amount of non-entrapped drug remaining in the 
aqueous supernatant. A Franz diffusion cell was used to monitor stavudine release 
from the nanoparticles. The formulations CF1, CF2, EF2 and EF3 showed good 
drug release from the polymer . The percentage cumulative drug release after 12 
hours was 75.54, 75.89, 78.86 and 76.42% respectively. However about 15% 
initial burst release was found at 1 hour in all formulations. EF2 released 78.86% 
of stavudine 12 hours with a burst drug release nearly 14.86% of drug within the 
initial 1 hour. Formulations 4 out of 8 showed good drug release from the 
polymer, the percentage cumulative drug release after 12 hours were in the range 
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of 72-78 %. Among the four formulations EF 2 (1% Chitosan & 1.5 % EudragitS 
100) showed maximum drug release in 12 hours diffusion study and good 
entrapment efficiency. In-vitro antiviral study revealed thatthe formulated 
nanoparticles were found to have good viral activity on viral cells in sustained 
manner. 
Umar Faruksha  A et al., 2013, formulated Pioglitazone Hydrochloride loaded 
Eudragit RL 100 nanoparticles by emulsification solvent evaporation method.  
The application of factorial design gave a statistically systematic approach for the 
formulation of nanoparticles.  Nanoparticles were characterized by Differential 
scanning calorimetry (DSC) and Scanning electron microscopy  (SEM).  Drug 
content, entrapment efficiency and particle properties such as size, size 
distribution and zeta potential were determined.  The designed nanoparticles have 
particle size from 136.7nm to 264.1nm and entrapment efficiency from 60.98% to 
76.41%.  Nanoparticles revealed a fast release during the first hour followed  by a 
more gradual drug release during a 24 hours period following a Fickian diffusion 
process. 32 factorial design thus facilitated the optimization of polymeric 
nanoparticulate carrier systems for sustained oral delivery of the drug. 
Srinivas P et al., 2012, formulated Moxifloxacin Hydrochloride loaded Eudragit 
RL 100  ocular nanoparticles  by solvent displacement method.  Different 
formulations by varying the ratios of drug and polymer and varying the ratios of 
organic and aqueous phase.  The formulations were evaluated in terms of particle 
size, Fourier transform infrared spectroscopy (FTIR), drug entrapment efficiency.  
The mean particle size for drug loaded formulations was found to be below 
200nm.  The zeta potential remained in the range of positive values for all batches 
+10mv to 40mv.  The invitro release studies suggest that release rate was related 
CHAPTER III                                                                         LITERATURE REVIEW	
 
Felodipine Polymeric Nanoparticles Reg.No.261211303           Page 41 
 
the drug:polymer ratio.  Increase of drug release was observed as a function of 
drug:polymer ratio.  In vivo studies were performed on New Zeland albino 
rabbits.  No ocular damage or abnormal clical signs to the cornea, iris or 
conjunctiva was visible.  The most suitable storage condition for nanoparticles of 
moxifloxacin hydrochloride was at 40C. 
Amulyaratna Behera et al., 2012, formulated Glibenclamide loaded poly (lactic-
co-glyclolic) acid (PLGA) nanoparticle by solvent evaporation technique using 
methanol/dichloromethane (2:1) and characterized by Differential scanning 
calorimetry (DSC) and Transmission electron microscopy (TEM). The effect of 
stirring speed (250, 1000, 1500 and 2500 rpm) and drug:polymer ratio (1:1, 1:2, 
1:3 and 2:1) on particle size, size distribution, zeta potential drug loading, 
encapsulation efficiency and drug release was also studied.  Stable Nanoparticles 
were successfully prepared without any incompatibility, as indicated by DSC and 
TEM studies, respectively.  As polymer and drug concentrations, and stirring 
speed increased, particle size, drug loading and encapsulation efficiency also 
increased.  Increase in polymer concentration sustained drug release but reverse 
was obtained as drug concentration increased. Controlled release biodegradable 
Glibenclamide nanoparticles can be efficiently prepared by emulsification solvent 
evaporation method suitable modulating processing variables. 
Kazutaka Higaki et al., 2012, formulated Paclitaxel loaded Polyethylene glycol 
and Polylactic acid block copolymer (PN-PTX)  nanoparticles by emulsion 
solvent diffusion method.  The physicochemical properties of  PN-PTX prepared 
were assessed the mean particle size was around 80nm and the zeta potential was 
found to be almost netural.  The invitro Paclitaxel release preoperty were assessed 
by a dialysis method.  Paclitaxel was stably incorporated in polymeric 
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nanoparticles for a long time in the presence of serum.  The in vivo 
pharmacokinetics of PN-PTX after intravenous administration was investigated in 
colon 26 tumor bearing mice.  The invivo disposition characteristics of PN-PTX 
were very favourable, then evaluated the anti tumor effect of PN-PTX in C26 
tumor bearing mice.  It is considered that the favourable pharmacokinetic 
properties of nanoparticles and the drug incorporated do not always lead to its 
potent in vivo pharmacological activity, suggesting the importance of Paclitaxel 
release properties with in tumor tissues. 
Dianrui Zhang et al., 2012, prepared Riccardin D nano suspension by 
evaportative precipitation into aqueous solution and the microfluidisation process.  
The characteristics of transmission electron spectroscopy, size distribution and 
zeta potential.  In the evaporative precipitation in to aqueous solution method, the 
drug was dissolved in the organic phase and F68, HPMC, PVP K 30 were 
dissolved in water the mass ratio of 2:1:2:1.  Differential Scanning Calorimetry 
(DSC) and X-Ray diffraction confirmed the crystalline states that were both 
reserved.  The solubility was greatly improved by the two methods and the EPAS 
nanocrystals were more soluble due to the smaller size.  An enhanced dissolution 
was obvious in vitro and the stable nanocrystals were successfully achieved by the 
two methods. 
Mahmood Alaei – Beirami et al., 2012, prepared Diclofenac Sodium loaded 
Eudragit RS 100 nanoparticles using nanoprecipitation – solvent deposition 
technique ( the single emulsion technique).  Particle size and size distribution of 
nanoparticles were studied by applying laser diffraction particle size analyzer, and 
morphology of the nanoparticles was also inspected by transmission electron 
microscopy (TEM).  All the prepared formulation using eudragit RS 100 resulted 
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in nano-range size particles with relative spherical smooth morphology and drug 
loading efficiency of nearly 100%.  Accroding to these findings, nanoprecipitation 
– solvent deposition technique was able to engineer diclofenac sodium – eudragit 
Rs 100 nanoparticles to reach target size that could undergo more studies for 
evaluation and comparison of the anti inflammatory effect of drug in nanoparticles 
with classical dosage forms following its ocular administration. 
Bharathi M et al., 2012, prepared valsartan loaded eudragit L 100 nanoparticles 
by nanoprecipitation method.  The nanoparticles were characterized by FTIR, 
DSC, SEM, Particle size analysis, Invitro diffusion and invivo studies are been 
performed.  The particle sizes of the nanoparticles were ranging from 175nm to 
232nm.  The formulation F2 in best drug release 60.38% at the end of 24 hours.  
Invivo studies revealed that in case of free drug, 40.9mcg/ml drug of maximum 
dose was recovered but in case of nanoparticles the dose recovered in serum was 
16.02mcg/ml after 6 hours.  The formulation stored at 40±10C was more stable 
compared to the other temperatures.  The feasibility of formulating valsartan 
loaded eudragit L 100 nanoparticles for the treatment of hypertensionby 
enhancing the bioavailability. 
Sankar V et al., 2012, formulated Zidovudine-Lamivudine loaded Poly (lactic-
co-glycolic acid) PLGA (50:50), Poly (lactic acid) PLA, Poly (methyl 
methacrylate) PMMA, methylmethacrylate-sulfopropylmethacrylate (MMA-SPM) 
by emulsion polymerization method.  The particle size and the surface 
morphology results revealed that PLGA nanoparticles (NPs) were smooth 
spherical with a size ranging from 58-224nm.  The drug content in lyophilized 
PLGA NPswas found to be 51.67% (Zidovudine) 58.33% (Lamivudine) and no 
drug loss was found after storage for 1 month at room temperature.  Invitro release 
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studies revealed that the rate of drug release from PLGA NPs was 95.38% in 10 
hours with zidovudine, and 97.37% in 10 hours with lamivudine which was 
slower, when compared to MMA-SPM, PLA and PMMA NPs.  The rate of drug 
release from MMA_SPM NPs was 64.33% in 10 hours with zidovudine and 
95.43% in 10 hours with lamivudine. Acute toxicity studies in mice revealed that 
the dose administered doses not induce mortality in test animal.  
Nepolean R et al., 2012, formulated Nisoldipine loaded Eudragit S 100 
nanoparticles by nanoprecipitation method. The interactions between the drug and 
polymer were investigated by Fourier transform infrared spectroscopy (FTIR) and 
Diffrential scanning colorimetry (DSC).  In vitro characteristics like particle size 
and size distribution, surface morphology and structural characterization, surface 
charges, drug content, entrapment efficiency, loading capacity and pH dependent 
drug release. The nanoparticles were in uniform shape, narrow size distribution 
with an average size of about 400nm.  In vitro release of Nisoldipine nanoparticles 
was found to be pH responsive and is evident for the controlled release of its 
payload only at colon to increase the bioavailability of  Nisoldipine by evading the 
cytochrome P 450 induced metabolism in liver and gut wall.  The experimental 
results indicate that Nisoldipine loaded Eudragit S 100 nanoparticles have better 
physicochemical characteristics and can be used as a drug carrier for targeted 
delivery of Nisoldipine in colon, in order to enhance its oral bioavailability. 
Mukesh S Patil et al., 2011,  prepared  and Optimized Simvastatin nanoparticles 
by nanoprecipitation  method using  partially water miscible solvents and the 
mutual saturation of the aqueous and organic phases prior to form a 
nanosuspension in order to reduce the initial thermodynamic instability of the 
nanoparticles.  It was possible to prepare aqueous dispersions of colloidal size 
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containing upto 30% w/v of Eudragit L 100 using methanol as a water miscible 
solvent with surfactant.  Simvastain was formulated as a nanoparticles in an 
attempt to increase its solubility and bioavailability. An optimized formulation of 
nanoparticles containing Simvastatin was developed through the experimental 
design, particle size analysis and zeta potential on oral administration in rats, 
nanoparticles provided significant increase in the bioabilability compared to a 
powder suspension formulation.  The nanoparticles have a higher surface to 
volume ratio as compared with bulk material and therefore the dose and frequency 
of administration would be reduced hence increasing patient compliance. 
Poovi G et al., 2011, formulated and optimized Repaglinide loaded Chitosan 
nanoparticles by solvent evaporation method in three different ratios.  The 
prepared nanoparticles were evaluated for particle size, Scanning Electron 
Microscopy (SEM), Fourier Transform Infrared Spectroscopy study (FT-IR), 
percentage yield, drug entrapment and for in vitro release kinetics.  Scanning 
Electron Microscopy exposed that nanoparticles were spherical in shape with a 
nearly smooth surface morphology.  Particle size was analyzed by Malvern 
particle size analyzer and shown 48-100nm range.  FT-IR Study reveals that, there 
was no interaction between Repaglinide and polymers.  The invitro drug release 
data to various kinetic equations indicated first order release, swelling and 
diffusion mechanism from Repaglinide nanoparticles.  The bioavailability of drug 
may be improved and may help to reduce the dose of the drug and frequency 
administration.  Controlled drug delivery system of poorly water soluble drugs 
like Repaglinide. 
Liang Fang et al., 2011, prepared Revaprazan Hydrochloride nanosuspension  by 
high pressure homogenization technique. Their crystalline state were evaluated by 
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DSC and Powder X-ray diffraction were used to study crystalline state of freeze 
dried powder of Revaprazan Hydrochloride suspensions.  The results showed that 
particles of Revaprazan Hydrochloride microsuspension and nanosuspension 
remained in the same crystalline state as coarse suspension.  The invitro 
dissolution test, both microsuspension and nanosuspension showed increased 
dissolution rate.  In vivo studies indicated that only nanosuspension could 
significantly increase oral bioavailability of Revaprazan Hydrochloride in rats.  
That means, in the case of particle size reduction, enhanced oral bioavailability 
can be achieved by reducing Revaprazan Hydrochloride particle size into nano 
range. 
Amar Singh et al., 2011,  formulated Losartan Potassium loaded Chitosan 
nanoparticles by ionic gelation of chitosan with tripolyphosphate anions.  
Nanoparticles of different core:coat ratio were formulated and evaluated for drug 
content, loading efficiency, particles size, zeta potential, invitro drug release and 
stability studies.  Scanning Electron Microscopy indicated that the nanoparticles 
were found to be in nanometer range and showed ideal surface morphology.  
Differential Scanning Calorimetry analysis indicated that there were no chemical 
interactions between drug and polymer and stability of drug, in vitro release 
behaviour from all the drug loaded batches were found to follow zero order and 
provided sustained release over a period of 24 hours.  The developed formulation 
overcomes and could possibility be advantageous in terms of sustained release 
dosage forms of losartan potassium. 
Gaurav  K Jain et al., 2011, prepared Atorvastatin loaded Chitosan nanoparticles 
by high pressure homogenization (HPH) method.  Scanning Electron Microscopy 
(SEM) revealed that Chitosan – Atorvastatin nano conjugate process smooth 
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surface where as X-ray diffraction (XRD) spectra demonstrated amorphous nature 
of nano conjugate.  Chitosan – Atorvastatin nano conjugate showed solubility 
enhancement of nearly 4 – fold and 100 – fold compared to Chitosan – 
Atorvastatin conjugate and pure Atorvastatin.  In vitro drug release studies in 
simulated gastric fluid and simulated intestinal fluid suggested sustained release of 
Atorvastatin from the conjugate.  The plasma concentration time profile of 
Atorvastatin after oral administration of CH – AT nano – conjugate (2574±95.4 
ng/mL) to rat exhibited nearly 5 fold increase in bioavailability compared with AT 
suspension (583±55.5 ng/mL).  AT suspension was also reduced when AT was 
administrated in form of CH – AT nano conjugate.  Chitosan conjugate nano 
prodrugs may be used as sustained polymeric prodrugs for enhancing 
bioavailability. 
Sowkar Baig et al., 2011, prepared Abacavir Sulfate loaded Alginates 
nanoparticles by in situ nano emulsion – polymer cross linking method.  The 
nanoparticles using different ratios of alginates and abacavir sulphate (ag-abs) in 
the ratios of (1:1, 1:2 and 1:3).  The encapsulation efficiency was also studied to 
find out the percentage drug entrapped in the prepared nanoparticles.  The result 
of ratio (1:3) showed a good encapsulation efficiency of 98.71%.  Abacavir 
Sulfate nanoparticle was confirmed by FT – IR, DSC and quantitated  by UV 
prepared nanoparticle appeared spherical with a dense drug core in transmission 
electron microscopy studies.  Hydro dynamic diameter of nanoparticles was 
63±0.235nm, with a Gaussian distribution and the zeta potential -0.6mev 
sustained diffusive drug release was observed in vitro, following zero order 
kinetics releasing the drug pay load over a period of 16 hr.  Embedding abacavir 
sulphate in alginate provided sustained release.  They also effered better 
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pharmacokinetic properties to the drug than that afforded by the free drug it self.  
The nanoparticle technique developed can be a good choice for the development 
of sustained anti retroviral drug carrier. 
Syam Potnuru et al., 2011, prepared Stavudine loaded Chitosan nanoparticles by 
solvent evaporation method, in situ nanoemulsion polymer cross linking method.  
In characterization the obtained particles size of nanoparticles is 65.5 – 176nm, 
size distribution and shape were done by using Scanning Electron Microscopy, 
zeta potential is for the best formulation.  According to release characteristics 
following the zero order release kinetics and release 16 hours.  Comparatively 
based upon the method of preparation in situ nanoemulsion polymer cross linking 
method and solvent evaporation method, the in situ method has produced a good 
results like drug loading efficiency, in vitro release studies, t90 , zeta potential and 
the corresponding formulation produced good results. 
Ji Jingou et al., 2011, prepared Methotrexate and Calcium folinate loaded 
Chitosan and Cyclodextrin nanoparticles by cross linking method.  The prepared 
nanoparticles were characterized by FT – IR Spectroscopy to confirm the cross 
linking reaction between chitosan and cross linking agent.  X-ray diffraction 
(XRD) was performed to reveal the form of the drug after encapsulation.  The 
average size of nanoparticles ranged from 308.4±15.22 to 369.3±30.01nm.  The 
nanoparticles formed were spherical in shape with high zeta potentials (higher 
than +30mv).  In vitro release studies in phosphate buffer saline (pH 7.4) showed 
an initial burst effect and followed by a slow drug release, cumulative release data 
were fitted to an empirical equation to compute diffusional exponent (n), which 
indicated the non Fickian trend for drug release. 
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Peng Liu et al., 2011, prepared Indomethacin and Itraconazole nanosuspension 
by wet milling technique.  4 types of stabilizers at 4 different concentrations were 
tested on 2 structurally different drug compounds.  Photon Correlation 
Spectroscopy results showed that the finest nanosuspensions were obtained when 
80 wt % ( to drug content) Pluronic F 68 was the stabilizer for Indomethacin and 
60 wt % Pluronic F 127 for Itroconazole compared physical mixtures, dissolution 
rates of the nanosuspensions showed significant increases.  The morphology of 
nanoparticles was observed by Transmission Electron Microscopy.  Crystalline 
state of the drugs before and after milling was confirmed using Differential 
Scanning Calorimetry and X-ray Powder Diffraction.  The physical and chemical 
stabilities of the nanosuspensions after storage for 2 months at room temperature 
and 40C were investigated using  TEM and HPLC.  No obvious changes in 
particle size and morphology and no chemical degradation of the drug ingredients 
were seen. 
Chi H Lee et al., 2011, prepared Sodium Fluorescein and Nile red loaded 
Eudragit S 100 nanoparticles by the modified quasi emulsion solvent diffusion 
method.  The nanoparticles had homogeneous surface morphology with spherical 
nature and uniformed texture.  In vitro release profile that model compounds were 
retained by the nanoparticles at vaginal pH.  But they were rapidly released from 
particles at physiological pH.  The nanoparticles cellular uptake by vaginal cells 
and subsequent drug release.  No cytotoxicity of the nanoparticles was detected in 
vaginal cell lines.  The pH sensitive Eudragit S 100 nanoparticles would be a 
potential carrier for not only topical delivery but also systemic delivery of 
therapeutically active compounds. 
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Suganeswari M et al., 2011, prepared Atorvastatin Calcium and Amlodipine 
Besylate nanoparticles by nanoprecipitation technique using PLGA, Eudragit RL 
Po as polymers and Pluronic F 68 as tribloere polymeric stabilizer.  The 
preformulation studies were carried out to confirm the solubility studies, 
Hygroscopicity and loss on drying for drug identification.  The prepared 
nanoparticles were assayed by HPLC to determine the drug content.  The 
morphological shape was confirmed by using Scanning Electron Microscopy.  
The particle size distribution was analyzed by using particle size analyzer.  The 
average mean particle size 550nm, 70nm, 80nm and 100nm respectively.  In vitro 
release maximum drug entrapment efficiency for both drugs Atorvastatin and 
Amlodipine.  In vivo release of drugs in a animal model.  The nanoparticulate 
suspension of amlodipine is to improve its absorption rate and therapeutic 
efficacy. 
Xuenong Zhang et al., 2011, prepared Cyclosporine A loaded Eudragit S 100 
nanoparticles.  The pharmacokinetic profile of freeze dried cyclosporine A 
Eudragit S 100 nanoparticles was studies with a random two way crossover study 
in dogs.  The drug blood concentration was determined by internal standard HPLC 
method after oral administration of Cyclosporine A , Eudragit S 100 nanoparticles 
and Neoral.  Pharmacokinetics parameters were calculated by 3P97 program.  The 
concentration time data were fitted as a two compartment open model.  The AUC 
of Cy-A-S-100 was higher than that of Neoral (P<0.05), while the CL 
significantly decreased (P<0.05).  The relative bioavailability of Cy-A-S-100 
nanoparticles were 135.9% compared with Neoral.  The bioavailability of CyA 
was significantly improved Cyclosporine A loaded Eudragit S 100 nanoparticles 
CHAPTER III                                                                         LITERATURE REVIEW	
 
Felodipine Polymeric Nanoparticles Reg.No.261211303           Page 51 
 
was a potential drug for developing a new Cyclosporine A nanoparticles solid 
formulation. 
Khosro Adibkia et al., 2010, prepared Naproxen loaded Eudragit RS 100 
nanoparticles by solvent evaporation/extraction technique ( the single emulsion 
technique).  The physicochemical characteristics of nanoparticles were studied 
applying particle size analysis, differential scanning calorimetry, X-ray 
crystallography, Fourier transform infrared spectroscopy and scanning electron 
microscopy.  To improve the physicochemical characteristics of the drug.  
Agitation speeds of homogenizer and drug/polymer ratio have no significant effect 
on the size of the nanoparticles.  The intermolecular interaction between Naproxen 
and Eudragit RS 100 was detected in the FT – IR Spectrum of the nanoparticles.  
It should be also evoked that all nanoparticles displayed a slowed release pattern 
with the reduced burst release in comparison with the intact drug powder and 
physical mixtures of drug and polymer. 
Swarnali Das et al., 2010, prepared Amphotericin –B loaded Eudragit RL 100 
nanoparticles by Solvent Displacement or Nanoprecipitation method.  The 
formulations are evaluated in terms of  particle size, zeta potential, and differential 
scanning calorimetry measurements.  All the formulations remained with in a size 
range of 130nm to 300 nm in fresh preparation as well as after 2 months.  The zeta 
potential was positive (+22 to +42mV) for all the formulations and was suitable 
for ophthalmic application.  The nanosuspensions produced a sediment, which 
was easy to redisperse by simple hand agitation.  No changes in macroscopic 
properties were observed.  The nanoparticles showed good stability in 20 to 60 C 
and at room temperature.  So they can be expected to be stable, safe and effective 
after long term storage.  In vivo studies suggest that Amphotericin B nanoparticles 
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can be expected to gain considerable attention for ocular antifungal effect and 
aminimal eye irritating effect. 
Bivash Mandal et al., 2010, prepared Sulfacetamide loaded Eudragit RL 100 
nanosuspension by solvent displacement method using acetone and pluronic F 108 
solution.  Drug to polymer ratio was selected as formulation variable.  
Characterization of the nanosuspension was performed by measuring particle size, 
zeta potential, Fourier transform infrared spectroscopy (FT-IR), Differential 
Scanning Calorimetry (DSC), Powder X-ray Diffraction (PXRD), drug 
entrapment efficiency and invitro release.  In addition, freeze drying, 
redispersibility and short term stability study at room temperature and at 40C were 
performed.  Spherical, uniform partices (size range below 500nm) with positive 
zeta potential were obtained.  No significant chemical interaction between drug.  
The prepared nanosupension exhibited good stability after storage at room 
temperature and at 40C.  Sucrose and Mannitol were used as Cryoprotectants and 
exhibited good water dispersibility of the FDN.  It could be utilized as potential 
delivery system for treating ocular bacterial infections. 
Mishra B et al., 2010,  formulated Lamotrigine nanosuspension by emulsification 
solvent diffusion method.  Characterized of the nanosuspension Fourier transform 
infrared (FT-IR), Differential scanning calorimetry, Partical size, polydispersity 
index (PDI) and zeta potential.   Nanoparticles were spherical with little surface 
adsorbed drug.  Properties of nanosuspensions in terms of size, zeta potential, poly 
dispersity index, entrapment efficiency, drug content and in vitro drug release 
were consistent and with in their acceptable ranges.  In vitro drug release studies 
suggested that nanosuspension might be used as a sustained delivery vehicle for 
Lamotrigine.  Statistical analysis revealed that size of the nanoparticles was most 
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strongly affected by stabilizer type while entrapment efficiency was influenced by 
the drug to polymer ratio.  Release rate seemed to be  governed by rate of 
diffusion of drug from polymeric matrix.  The formulation remained reasonably 
stable up to 3 months under stressed storage conditions. 
Rezaei Mokarram A et al., 2010, prepared Indomethacin loaded Polyvinyl 
pyrrolidine (PVP) Nano Solid Suspension by controlled precipitation technique, 
characterized by differential scanning calorimetry (DSC), X-ray diffraction 
(XRD), Fourier Transform Infrared Spectroscopy (FTIR) and evaluated for in 
vitro solubility and dissolution rate .  Absence of thermal and diffractional peaks 
in DSC and XRD studies indicated that indomethacin interacts with PVP in solid 
phase.  The solubility of indomethacin in nano solid suspension compared to 
crystalline form was increased to about four fold.  It was found that particle size 
distribution depend to the polymer molecular weight and drug:polymer ratios.  
TEM results as amorphous  nanosize particles in freeze dried powder.  Enhanced 
solubility and dissolution rate of indomethacin compared to physical mixtures and 
crystalline form of indomethacin demonstrated that it interacts with PVA via 
hydrogen bond and probably forming eutectic mixture. 
Mitra Jelvehgari et al., 2010,  prepared Theophylline loaded  poly (- 
caprolactone) nanoparticles by using water in oil in water (w1/o/w2  double 
emulsion solvent diffusion / evaporation method) taking different ratios of 
drug/polymer.  Solvent systems consist of ethyl acetate and dichloromethane for 
microspheres and nanospheres respectively.  In the current study formulations 
were characterized by loading efficiency, yield, particle size, zeta potential, X-ray 
diffraction and differential scanning calorimetry (DSC).  The XRD and DSC 
showed stable character of theophylline in the drug loaded microspheres.  The 
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drug release was found to be diffusion and erosion controlled.  The burst was 
significantly lower with composite microparticles and may be explained by lower 
diffusion of the drug from double polymeric wall formed by the nanoparticles 
matri followed by another diffusion step through the microparticle polymeric wall. 
Anilkumar J Shinde et al., 2010, prepared Simvastatin loaded polylactic-co-
glycolic acid nanoparticles by precipitation solvent deposition method using 32 
full factorial design.  The prepared formulations were further evaluated for drug 
content, invitro drug release pattern, short term stability and drug excipient 
interactions.  The application of factorial design gave a statistically systematic 
approach for the formulation and optimization of nanoparticles with desired 
particle size and high entrapment efficiency.  Drug:polymer ratio and 
concentration of stabilizer were found to influence the particle size and 
entrapment efficiency of simvastatin loaded PLGA nanoparticles.  Invitro drug 
release study of selected factorial formulations.  The release was found to follow 
first order release kinetics with Fickian diffusion mechanism for all batches.  
These results indicate that simvastatin loaded PLGA nanoparticles could be 
effective in sustained drug release for a prolonged period. 
Rathi J C et al., 2009, formulated Lamivudine loaded polymethacrylic acid 
nanoparticles in different drug to polymer ratio by nanoprecipitation method.  
SEM indicated that nanoparticles have a discrete spherical structure without 
aggregation.  The average particle size was found to be 121±8 - 403±4nm.  The 
particle size of the nanoparticles was gradually increased with increase in the 
proportion of polymethacrylic acid polymer.  FT-IR studies indicated that there 
was no chemical interaction between drug and polymer and stability of drug.  The 
invitro release behaviour from all the drug loaded batches was found to be zero 
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order and provided sustained release over a period of 24 hours.  The slow and 
constant release of Lamivudine from nanoparticles maintain constant drug plasma 
concentration thereby increasing therapeutic efficacy. 
Yadav A V et al., 2009, formulated Carvedilol loaded Eudragit E 100 
nanoparticles by the nanoprecipitation method using polymeric stabilizer 
poloxamer 407.  Nanoparticles of carvedilol were obtained with high 
encapsulation efficiency,  The particles were characterized for particle size by 
photon correlation spectroscopy and transmission electron microscopy.  The 
particle size of the prepared nanoparticles ranged from 190nm – 270nm.  
Nanoparticles of carvedilol were obtained with high encapsulation efficiency 85-
91%.  This formulation approach can be used to improve the therapeutic efficacy 
of poorly soluble drugs. 
Julijana Kristl et al., 2009, studied the advantages of Celecoxib nanosuspension 
by emulsion – diffusion method using three different stabilizers tween80, PVP K 
30 and SDS.  The nanosuspension characterized by particle size analysis, 
dissolution testing, scanning electron microscopy imaging, differential scanning 
calorimetry and X-ray powder diffraction.  Spray dried nanosuspension was 
blended with microcrystalline cellulose, and compressed to tablets and their 
tensile strength, porosity and elastic recovery of tablets.  The crystalline nano 
sized celecoxib alone or in tablets showed a dramatic increase of dissolution rate 
and extent compared to micronized.  Markedly lower compaction forces are 
needed to compress tablets with nanosized compared to microsized celecoxib 
powder to produce tablets of equal tensile strength.  Thus possibly improve their 
oral bioavailability. 
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Adlin Jino Nesalin J et al., 2009, formulated Flutamide loaded Chitosan 
nanoparticles by ionic gelation technique.  Characterization of nanoparticles 
particle size analysis, estimation of percentage yield and drug loading capacity of 
chitosan nanoparticles, invitro drug release studies.  SEM analysis their size 
distribution was found to be 400nm.  The drug loading capacity of nanoparticles 
containing drug:polymer in various ratios.  Thus there was a steady increase in the 
entrapment efficiency on increasing the polymer concentration in the formulation.  
In vitro release of Flutamide showed a very rapid initial burst, and then followed 
by a very slow drug release.  From the drug release studies it was observed that 
nanoparticles prepared with chitosan in the core:coat ratio 1:4 gives better 
sustained release for about 12 hours as compared to other formulations. 
Sanjay Singh et al., 2009, prepared Risperidone loaded poly (D,L- lactide - co – 
glycolide) (PLGA) nanoparticles by nanoprecipitation method using polymeric 
stabilizer (Poloxamer 407).  The nanoparticles were characterized for particle size 
by photon correlation spectroscopy and atomic force microscopy.  The invivo 
efficacy (antipsychotic effect) of prepared formulations (nanoparticles and in situ 
gel containing nanoparticles) was studied by administering them subcutaneously 
to mice.  Extrapyramidal side effects of the formulations were also studied.  The 
particle size of the prepared  nanoparticles ranged between 85 and 219 nm.  About 
89% to 95% drug encapsulation efficiency was achieved when risperidone was 
loaded at 1.7% to 8.3% by weight of the polymer.  During in vivo studies prepared 
risperidone formulations showed n antipsychotic effect that was significantly 
prolonged over that of risperidone solution for up to 72 hours with fewer 
extrapyramidal side effects.  The prolonged effect of risperidone was obtained 
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from the risperidone formulations administered subcutaneously, and this may 
improve the treatment of psychotic disorders by dose reduction. 
Le Thi Mai Hoa et al., 2009, prepared Ketoprofen loaded Eudragit E 100 
nanoparticles by emulsion solvent evaporation method.  The morphology structure 
was investigated by scanning electron microscopy (SEM).  The interactions 
between the drug and polymer were investigated  by Fourier Transform Infrared 
Spectroscopy (FTIR).  The size distribution was measured by means of Dynamic 
Light Scattering.  The SEM observations give the surface morphological features, 
morphology of particles was spherical and homogeneous.  The size distribution of 
the nanoparticles prepared was found in the range from 50 to 200nm, the mean 
diameter was 150nm.  The interaction between the drug and the polymer was 
determined by Fourier Transform Infrared Spectroscopy.  The carboxylic group of 
the Ketoprofen molecule interacts with the Eudragit. 
Jawahar N et al., 2009, prepared carvedilol loaded PLGA nanoparticles by 
Nanoprecipitation method.  Nanoparticles were examined for physicochemical 
characteristics, invitro release kinetics and invivo biodistribution studies.  Average 
size of the nanoparticles were in range of 132-234nm.  The drug encapsulation 
efficiency was 77.6% at 33% drug loading.  Invitro cumulative release from the 
nanoparticles was 72% at 24 hours.  Invivo biodistribution studies in rats revealed 
that these particles are distributed in heart, liver and kidney at higher 
concentration may allow their delivery to target sites.  Sustained release of 
nanoparticles might extend the circulation time of drug will suitable for reducing 
the initial hypotensive peak and prolong the antihypertensive effect.  
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Weigen Lu et al., 2008, prepared Nimodipine nanosuspension compared with 
commercially available ethanol solution.  Nimodipine nanosuspension by high 
pressure homogenization.  The effects of the production parameters such as 
pressure, cycle numbers and crushing principles on the mean particle size, 99% 
diameter and polydispersity of  the nanosuspension were investigated.  
Characterization of the product was performed by Scanning Electron Microscope 
(SEM) and Differential Scanning Calorimeter (DSC).  The number of large 
particles in the Nimodipine nanosuspension was much fewer than that of the fat 
emulsions for parenteral nutrion.  The saturation solubility was increased as the 
reduction of particle size into nanometer range, which led to the fast dissolution of 
drug nanocrystals.  The aqueous nanosuspension might be a good choice for 
intravenously administrating poor soluble nimodipine, which is proved to have the 
lower intravenous irritation and incidence of phlebitis than ethanol product. 
Rainer H Muller et al., 2008, prepared Ascorbyl Palmitate nanosuspensions by 
high pressure homogenization method.  The physicochemical properties of 
Ascorbyl Palmitate  nanosuspensions ( mean nanocrystal size, zeta potential and 
chemical stability) were found to be dependent on the type of stabilizer ( 
surfactant).  It was found that the mean size of Ascorbyl  Palmitate 
nanosuspensions stabilized with tween80 remained in the nanometer range and the 
amount of active determined by HPLC was more than 90% when stored at three 
different temperatures during 3 months.  The obtained results after lyophilization 
revealed that the nanocrystal agglomeration of formulations lyophilized with out 
trehalose was more pronounced than those with trehalose.  From the X-ray 
diffractorgrams, it was shown that Ascorbyl Palmitate remained in a crystalline 
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state which is physicochemically and thermodynamically more stable than 
Ascorbyl Palmitate in an amorphous state. 
Ravikumar M N V et al., 2007, prepared Estradiol loaded PLGA Nanoparticles 
by emulsion diffusion evaporation method employing didodecyldimethyl 
ammonium bromide (DMAB) as stabilizer.  The effect of polymer molecular 
weight and copolymer composition on particle properties and release behaviour.  
Drug release in vitro decreased with increase in molecular weight and lactide 
content of PLGA.  In vivo data showed that with all the PLGA nanoparticulate 
formulations, same dose ( 1mg estradiol/rat) produced detectable blood levels for 
5-11 days, depending on the molecular weight, copolymer composition and 
resultant particle size, compared to 1 day profile shown by pure drug.  Thus, 
estradiol loaded PLGA nanoparticles can be effective in improving the oral 
bioavailability and decreasing the dosing frequency , there by minimizing the dose 
dependent adverse effects and maximizing the patient’s compliance. 
Annick Ludwig et al., 2006, prepared Ciprofloxacin loaded Eudragit Rs 100 or 
Eudragit RL 100 and PLGA nanoparticles by water - in - oil - in – water (w/o/w) 
emulsification and solvent evaporation, followed by high pressure 
homogenization.  Two non biodegradable positively charged polymers, Eudragit 
RS 100 and RL 100, the biodegradable polymer poly (lactic - co - glycolic acid) or 
PLGA were used alone or in combination, with vaying ratios.  The formulations 
were evaluated in terms of particle size and zeta potential.  Differential Scanning 
Calorimetry measurements were carried out on the nanoparticles and on the pure 
polymers Eudragit and PLGA.  Drug loading and release properties of the 
nanoparticles were examined.  The antimicrobial activity aganist pseudomonas 
aeruginosa and staphylococcus aureus was determined.  The mean diameter was 
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dependent on the presence of  eudragit and on the viscosity of the organic phase.  
The zeta potential of all eudragit containing nanoparticles was positive in 
ultrapure water (around ±21/±25mV).  The particles activity against P.aeruginosa 
and S.aureus was comparable with an equally concentrated ciprofloxacin solution. 
Qiang Zhang et al., 2004, prepared Cyclosporine A loaded poly (methacrylic 
acid and methacrylate) copolymer nanoparticles using an adaptation of the quasi-
emulsion solvent diffusion technique.  The characterization and the dispersion 
state of CyA at the surface or inside the polymeric matrices of the nanoparticles 
were investigated.  The invitro release studies were conducted by Ultracentrifuge 
method.  The bioavailability of CyA from nanoparticles was neural 
microemulsion was assessed in Sprague- Dawley (SD) rats at a dose of 15mg/kg.  
The particle size of the nanoparticles  was within the range from 37.4±5.6 to 
106±14.8nm.  The drug entrapped efficiency was very high and in all cases the 
drug was amorphous or molecularly dispersed within the nanoparticles polymeric 
matrices.  In vitro release experiments revealed that the nanoparticles exhibited 
perfect pH dependant release profiles.  The relative bioavailability of CyA was 
markedly increased by 32.5% for CyA - S 100 nanoparticles (P<0.05), and by 
15.2% and 13.6% for CyA - L - 100 - 55 and CyA L 100 nanoparticles 
respectively.  While it was decreased by 5.2% from CyA - E 100 nanoparticles 
when compared with the neural micromulsion with these results, the potential of 
pH sensitive nanoparticles for the oral delivery of CyA was confirmed. 
Esko I Kauppinen et al., 2003, prepared Beclomethasone Dipropionate loaded 
Eudragit E 100 or Eudragit L 100 nanoparticles by a novel aerosol flo reactor 
method.  Particle size and morphology, crystallinity, and thermal behaviour were 
determined as a function of particle composition.  It was found that all the 
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nanoparticles produced, regardless of particle composition, had geometric number 
mean diameters of approximately 90nm, and were spherical showing smooth 
surfaces.  The drug was molecularly dispersed in the amorphous polymeric matrix 
of the nanoparticles, and drug crystallization was not observed when the ambient 
temperature was below the glass transition temperature of the polymer. 
Silvia S Guterres et al., 2003, prepared Diclofenac loaded miglylol 810 or benzyl 
benzoate and poly (ε-caprolactone) or Eudragit S 90 nanocapsule and nanosphere 
suspensions by nanoprecipitation and freeze dried after the addition of colloidal 
silicon dioxide.  The powders were examined under scanning electron microscopy 
and gastro intestinal tolerance of products was evaluated in rats powders presented 
drug contents between 90.2±5.5% and 101.1±1.9% (HPLC). SEM analyzes 
showed non spherical microparticles and at higher magnifications, the 
micropowder surface presented a homogeneous nanocovering.  Regarding the 
gastrointestinal tolerance, with the exception of benzyl benzoate loaded 
formulations powders presented loaded formulations powders presented lesional 
indexes lower than the diclofenac salt solution.  In contrast to the literature, nano 
capsules can be dried by freeze drying with out leakage of drug or breaking the 
capsule wall. 
Kristl J et al., 2002, prepared Enalaprilat loaded poly- (lactide - co - glycolide) 
(PLGA) and polymethyl methacrylate (PMMA) nanoparticles by the 
emulsification diffusion method.  Characterized according to particle size, zeta 
potential, entrapment efficiency and physical stability.  Effective permeabilities 
through rat jejunum of the enalaprilat in solution and in enalaprilat loaded 
nanoparticles were compared using side by side diffusion chambers.  The 
solubility of enalaprilat is very low.  The diameters of drug loaded PMMA and 
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PLGA nanoparticles were 297 and 204nm.  The mean nanoparticle size and the 
polydispersity index were found to decrease with increasing PVA concentration.  
In vitro release studies show a biphasic release of enalaprilat from nanoparticle 
dispersions fast in the first step and very slow in the second.  Ex vivo transport 
through isolated rat jejunum of enalaprilat in solution with that of enalaprilat in 
nanoparticle dispersions. 
Snjezana Stolnik et al., 1999, prepared  Procaine Hydrochloride loaded poly (DL 
- lactide - co- glycolide) (PLGA) nanoparticles by the nanoprecipitation method in 
water pH 5.8 as the aqueous phase.  The nanoparticles produced were submicron 
size (<210nm) and low polydispersity.  Drug content and drug entrapment were 
very low.  This study therefore investigated the influence of various formulations 
variables on enhancing the incorporation efficiency of procaine hydrochloride.  
An increase in the aqueous phase pH from 5.8 to 9.3 enhanced the drug  content 
and drug entrapment which may be due to a decreased degree of ionisation and 
hence lower solubility in the aqueous phase.  Drug release from nanoparticles 
appears to consist of two components with an initial rapid release followed by a 
slower exponential stage.  This study has demonstrated that formulation variables 
can be exploited in order to enhance the incorporation of a water soluble drug. 
Philippe Maincent et al., 1998, prepared Isradipine loaded poly (epsilon - capro - 
lactone), poly (D,L - lactide) and poly (D,L - lactide - co - glycolide) by 
nanoprecipitation method.  In vitro scanning electron microscopy and differential 
scanning calorimetry were used to characterize the nanoparticles.  The average 
diameters of the nanoparticles ranged from 110nm to 208nm.  The zeta potential 
of the nanoparticles was negative, with values of about -25mV which promoted 
good stabilization of the particles.  X-ray diffraction and differential scanning 
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calorimetry have shown the amorphous state of  PLA 100 and PLAGA 
nanoparticles and the semi crystalline state of PCL.  In all types of nanoparticles 
non-crystalline isradipine was found in the polymer which suggests a molecular 
dispersion of the drug in the matrix.  To reduce the initial hypotensive peak and to 
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CHAPTER-IV 
AIM AND OBJECTIVE OF THE WORK 
Hypertension is one of the most common disorders throughout the world.  
Managing hypertension continues to be challenging with the currently available 
drugs, since they have poor bioavailability by oral route and due to toxicity at higher 
doses.  The solubility and dissolution behaviour of a drug is the key determinant to its 
oral bioavailability.  Improvement of oral bioavailability of poor water soluble drugs 
remains to be one of the most challenging aspects of drug development. 
Felodipine is a BCS class II drug which has poor solubility and high 
permeability.  It is a dihydropyridone calcium channel blocker which acts by 
decreasing smooth muscle contractility and subsequent vasoconstriction by inhibiting 
influx of calcium ions through voltage gated L-type calcium channels. Inhibition of 
initial influx of calcium decreases the contractile activity of smooth muscle cells and 
results in vasodilation, leading to overall decrease in blood pressure.  Felodipine is 
used in the management hypertension.  As given in conventional dosage form, oral 
bioavailability is very less i.e, 15% and the biological half life is 11 to 16 hours. 
Nanoparticulate drug delivery system is one of the best approaches to enhance 
the dissolution rate and solubility of drugs suffer from oral bioavailability problems. 
Polymeric nanoparticles are the colloidal drug delivery system with a particle size of 
10 – 1000 nm that potentially delivers the therapeutic agent in the systemic circulation 
in a controlled manner. 
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The main objective of this study is to formulate and evaluate oral 
nanoparticulate delivery of felodipine using the polymers eudragit L 100 and eudragit 
S 100 along with stabilizers pluronic F 68 and polyvinyl alcohol. And, this approach 
suggests that this  polymeric nanoparticles will be a promising delivery system to 
improve the oral bioavailability as well as to maintain its therapeutic activity in a 
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CHAPTER V 
PLAN OF WORK 
1. PREPARATION AND STANDARD CURVES FOR FELODIPINE: 
a. Preparation of calibration medium     
b. Estimation of absorption maximum (λmax) 
c. Preparation of  standard curve of Felodipine using Distilled water, 0.1N 
Hydrochloric acid, Phosphate buffer pH 6.5and Phosphate buffer pH 7.4  
 
2. DRUG –POLYMER INTERACTION STUDIES: 
     a. Fourier Tranform Infrared spectroscopic analysis (FT-IR) 
3. FORMULATION OF FELODIPINE LOADED POLYMERIC  
    NANOPARTICLES  
 
4. CHARACTERIZATION OF FELODIPINE LOADED POLYMERIC        
    NANOPARTICLES:   
    a. Determination of drug content 
    b. Determination of drug entrapment efficiency 
    c. Determination of particle size, polydispersity  Index & zeta potential                      
    d. In vitro release studies of felodipine loaded polymeric nanoparticle using  
       dialysis membrane 
e. Kinetics of drug release studies 
f. Selection and evaluation of best formulation 
i. Lyophilization of nanosuspensions 
ii. Infrared Spectroscopic analysis  
iii. Solubility measurement studies 
iv. Morphology of polymeric nanoparticles by SEM analysis 
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CHAPTER VI 
MATERIALS AND EQUIPMENTS 
MATERIALS  USED: 








Eudragit L 100 (Polymethacrylic 
acid, methylacrylate,1:1) 




Eudragit S 100 (Polymethacrylic 
acid, methylacrylate,1:2) 




Pluronic F 68 (Poloxamer 188) 




PVA ( Poly Vinyl Alcohol) 






Monobasic Sodium Phosphate 
Monohydrate 
Sigma Aldrich , USA. 
8 
Dibasic Sodium Phosphate 
anhydrous 
High purity laboratory chemicals, 
Mumbai. 
9 Sodium Lauryl Sulfate 
High purity laboratory chemicals, 
Mumbai.. 
10 Sodium Hydroxide 
High purity laboratory chemicals, 
Mumbai. 
11 Hydrochloric Acid Universal Scientifics, Madurai. 





High purity laboratory chemicals, 
Mumbai. 
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EQUIPMENTS USED: 
S.NO EQUIPMENTS SUPPLIERS 
1 Electronic weighing balance A & D Company, Japan 
2 UV-Visible spectrophotometer Shimadzu Corporation, Japan 
3 
 
FT-IR (Fourier transform Infrared 
spectrophotometer) 
Shimadzu, Japan. 
4 Differential Scanning Calorimetry DSC Q 200, Mumbai. 
5 Homogenizer M.S.E Ltd, England. 
6 Refrigerator Kelvinator, India. 
7 Cooling Centrifuge Apparatus Eppendorf Centrifuge 5417R, Germany 
8 Scanning electron microscope Hitachi X 650,Tokyo Japan. 
9 Particle size analyser 
Nano ZS 9o,Malvern Instruments Ltd 
U.K. 
10 Environmental chamber Inlab equipments Pvt. Ltd. Madras 
11 Mechanical shaker Secor, India. 
12 Scanning electron microscope Hitachi X650, Tokyo, Japan. 
13 Ultra Sonicator Vibronic’s Ultrasonic processor, India. 
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Drug properties: 
Nature   :A white or light yellow, crystalline powder. 
Melting point  :145°. 
Molecular weight :384.3. 
Solubility  :  Freely soluble in methyl alcohol, dehydrated alcohol, in 
                                   acetone and dichloromethane.                                
 Log p   :3.86 
Half life  :11 to 16 hours (oral administration in normal patients); 
                                      2 hours (patients with renal failure).   
(Martindale 36th Edition ,Clarke’s Analysis of Drugs and Poisons 3rd Edition & 
Drugbank.com). 
Pharmacodynamics: 
 Felodipine belongs to the dihydropyridine (DHP) class of calcium channel 
blockers (CCBs), the most widely used class of CCBs.  There are at least five 
different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type.  It 
was widely accepted that CCBs target L-type calcium channels, the major channel in 
muscle cells that mediates contraction; however, some studies have shown that 
felodipine also binds to and inhibits T-type calcium channels.  T-type calcium 
channels are most commonly found on neurons, cells with pacemaker activity and on 
osteocytes. The pharmacologic significance of T-type calcium channel blockade is 
unkown.  Felodipine also binds to calmodulin and inhibits calmodulin-dependent 
calcium release from the sarcoplasmic reticulum.  The effect of this interaction 
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appears to be minor.  Another study demonstrated that felodipine attenuates the 
activity of calmodulin-dependent  cyclic nucleotide phosphodiesterase (CaMPDE) by 
binding to the PDE-1B1 and PDE-1A2 enzyme subunits.  CaMPDE is one of the key 
enzymes involved in cyclic nucleotides and calcium second messenger systems.  
Felodipine also acts as an antagonist to the mineralocorticoid receptor by competing 
with aldosterone for binding and blocking aldosterone-induced coactivator 
recruitment of the mineralocorticoid receptor.  Felodipine is able to bind to skeletal 
and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in 
muscle contraction.  Though felodipine exhibits binding to many endogenous 
molecules, its vasodilatory effects are still thought to be brought about primarily 
through inhibition of voltage-gated L-type calcium channels.  Similar to the DHP 
CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive 
conformation.  Since arterial smooth muscle depolarizations are longer in duration 
than cardiac muscle depolarizations, inactive channels are more prevalent in smooth 
muscle cells.  Alternative splicing of the alpha-1 subunit of the channel gives 
felodipine additional arterial selectivity.  At therapeutic sub-toxic concentrations, 
felodipine has little effect on cardiac myocytes and conduction cells.(Drugbank.com). 
Mechanism of action: 
 Felodipine decreases arterial smooth muscle contractility and subsequent 
vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type 
calcium channels.  It reversibly competes against nitrendipine and other DHP CCBs 
for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells.  
Calcium ions entering the cell through these channels bind to calmodulin.  Calcium-
bound calmodulin then binds to and activates myosin light chain kinase (MLCK).  
Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit 
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of myosin, a key step in muscle contraction. Signal amplification is achieved by 
calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine 
receptors.  Inhibition of the intial influx of calcium decreases the contractile activity 
of arterial smooth muscle cells and results in vasodilation.  The vasodilatory effects of 
felodipine result in an overall decrease in blood pressure.  Felodipine may be used to 
treat mild to moderate essential hypertension.(Drugbank.com). 
Pharmacokinetic properties: 
 
 Absorption :  
 Is completely absorbed from the gastrointestinal tract; however, extensive first 
pass metabolism through the portal circulation results in a low systemic availability of 
15%. Bioavailability is unaffected by food. 
Volume of  Distribution :  
 Apparent volume of distribution, 10 L/Kg (normal patients); 5.6 L/Kg 
(patients with cirrhosis). 
Protein binding:  
 Felodipine is approx 99% bound to plasma proteins, mainy albumin. 
Metabolism :  
 Hepatic metabolism primarily via cytochrome P 450 3A4. Six metabolites 
with no appreciable vasodilatory effects have been identified.     
Excretion :   
 Is excreted almost entirely as metabolites, about70% of a dose being excreted 
in urine and the remainder in faeces.      
Dose : 
  Tablet oral - 2.5mg,5mg & 10mg. 
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Usual Adult Dose for Hypertension: 
1. Initial dose : 5 mg daily, adjusted as required. 
     2.   Maintenance dose : 2.5 mg to 10 mg daily and doses above 20mg daily not 
usually needed. 
Usual Adult Dose for Angina: 
 Initial dose: 5mg daily increased if necessary to 10mg daily. 
Adverse drug  reactions:   
       Serious:  
 Arrhythmias, MI, AV block, palpitations, hypotension, tachycardia, peripheral 
edema.  
       Others:  
 Headache, drowsiness, dizziness, anxiety, diarrhea, gingival hyperplasia, 
facial edema, pharyngitis. 
Drug interactions: 
The barbiturate, amobarbital, aprobarbital, butabarbital, butalbital butethal, 
heptabarbital,hexobarbital,methylphenobarbitalmethohexital,pentobarbital,pri
midone,quinidine barbiturate  secobarbital, talbutal. 
Contraindications:   
 Hypersensitivity, Severe hepatic impairment, Cirrhosis or Biliary 
obstruction.Primary hyper aldosteronism, Pregnancy, Lactation. 
 
International brand names available in the market:  
Plendil, Felogard, Renedil. 
Storage: 
 Store in airtight containers,  Protect from light. 
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Description: 
1. Nature                                     :  White, free flowing powder. 
2. Polymer dry weight content   :  95% 
3. Recommended solvents          :  acetone, alcohols. 
4. Acid value                               :  300 – 330. 
5. Density                                    :  0.831 – 0.852g/cm3 
Functional category:  
1. Film former 
2. Tablet binder 
3. Tablet diluent 
Stability and storage conditions: 
                 Dry powders are stable for a period of 3 years if stored in a tightly closed 
container at less than 30o C. Dispersions should be stored at temperatures between       
5 oC and 25 oC and are stable for a period of 18 months. 
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Description: 
1. Nature                                     :   White, free flowing powder. 
2. Polymer dry weight content    :   95% 
3. Recommended solvents          :   acetone, alcohols. 
4. Acid value                               :   180 -200. 
5. Density                                    :   0.831 – 0.852g/cm3. 
Functional category:     
1. Film former 
2. Tablet binder 
3. Tablet diluent 
Stability and storage conditions: 
Dry powders are stable for a period of 3 years if stored in a tightly closed 
container at less than 30o C. Dispersions should be stored at temperatures between      
5 oC and 25 oC and are stable for a period of 18 months. 
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HLB value  :  29 
Melting point  :  52o C - 57oC. 
Solubility        :  Freely soluble in 95% ethanol, water 
 
Functional Category : 
1. Dispersing agent                          
2. Coemulsifying agent;  
3. Solubilizing agent 
4. Tablet lubricant 
5. Wetting agent. 
 
Storage :         
 Should be stored in a well-closed container in a cool and dry place. 
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Melting point        : 2280C for fully hydrolyzed grades; 180-1900C 
     for partially hydrolyzed grades. 
Specific gravity : 1.19-1.31 for solid at 250C. 
Specific heat  : 1.67 J/g (0.4 cal/g) 
Functional Category: 
1. Coating agent 
2. Lubricant 
3. Stabilizing agent 
4. Viscosity-increasing agent 
Stability and storage conditions:   
 Polyvinyl alcohol is stable when stored in a tightly sealed container in a cool, 
dry place.  Aqueous solutions are stable in corrosion-resistant containers.  
Preservatives may be added to the solution if extended storage is required.  Polyvinyl 
alcohol undergoes slow degradation at 1000C and rapid degradation at 2000C; it is 















CHAPTER IX                                                              EXPERIMENTAL PROTOCOL	
 
Felodipine Polymeric Nanoparticles Reg.No.261211303          	 Page	82	
 
CHAPTER - IX 
EXPERIMENTAL PROTOCOL 
1. PREPARATION AND STANDARD  CURVES  FOR  FELODIPINE 
a. Preparation of calibration medium 
    0.1N Hydrochloric Acid with 0.1% w/v SLS 
 A known volume of 8.5ml Hydrochloric acid is dissolved in distilled water 
and  add 1 gm Sodium lauryl sulphate the volume is made up to 1000ml. 
(IndianPharmacopoeia., 2010). 
     Phosphate Buffer pH 6.5 with 0.1% w/v SLS 
 A  known volume of 100ml of phosphate buffer pH 6.5 with 0.1 percent 
sodium lauryl sulphate prepared by diluting 41.2ml of 1M monobasic sodium 
phosphate monohydrate, 39.2 ml of 0.5M dibasic sodium phosphate anhydrous, and 1 
gm of sodium lauryl sulphate to a 1000ml volumetric flask. Add 900ml of distilled 
water, adjust with 1M sodium hydroxide to volume with distilled water. 
(IndianPharmacopoeia., 2010 & U S Pharmacopoeia., 2007). 
    Phosphate buffer saline (PBS) pH 7.4 with 0.1% SLS 
A known quantity of (2.38 g) of disodium hydrogen phosphate, 0.19 g of 
potassium dihydrogen phosphate and 8 g of sodium chloride are dissolved in 
sufficient quantity of distilled water and made upto 1000ml. 
b. Estimation of absorption maximum (λmax) 
A known weight (10mg) of drug (Felodipine) is  dissolved in 100ml of 
methanol   to form a primary stock solution (100µg/ml). The stock solution is further 
diluted with acid  buffer 0.1N Hydrochloric acid with 0.1% w/v SLS and  phosphate 
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buffer pH 6.5 with 0.1% w/v SLS solution separately to make (10µg/ml) 
concentration. The resultant solutions is scanned in the range of  (200-400nm) by  UV 
Spectrophotometer to get absorption maximum(λ max). 
c. Preparation of standard curves 
The primary stock solution is further diluted with  0.1N Hydrochloric acid 
with 0.1% w/v SLS, to obtain a series of solution  in the concentration range  of (5 to 
25µg/ml). The absorbance of the solutions are measured at λmax (362nm) by UV- 
spectrophotometer. A standard curve is plotted using concentration on X-axis and the 
absorbance obtained on Y-axis. Similarly,  a standard  curve is also  plotted  using  pH 
6.5 with 0.1% w/v SLS  buffer solution.(Sandeep Kumar D et al., 2011, Patel V P et al 
2011 &  Hariprasanna R C et al., 2010). 
2. DRUG POYMER INTERACTION STUDIES 
    Compatibility studies 
           Fourier Transform Infrared Spectroscopy (FT-IR) are carried out to check the 
compatibility between the drug and the polymer. 
a. Fourier Transform Infrared Spectroscopic analysis (FT-IR) 
          Fourier Transform Infrared  Spectrum  analysis  of drug (Felodipine), polymers  
(Eudragit L & S 100) surfactants(Pluronic F 68 & Polyvinyl Alcohol) are obtained 
from FT-IR Spectrophotometer (Shimadzu,Japan)  by KBr disk method. It is an 
important tool plays a major role in determining the compatibility between the drug 
and polymer. A known weight of  samples are mixed with KBr powder and 
compressed to 10-mm discs by hydraulic  press  at  pressure  of  150  bar  for  30 s. 
The  scanning  range  and  resolution  are 400 – 4000cm-1 and 4cm1.The spectra 
obtained are compared and interpreted for the shifting of functional peaks  or the 
appearance and disappearance of new functional peaks.(Mishra B et al., 2010). 
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3. FORMULATION OF  FELODIPINE  LOADED  POLYMERIC  
    NANOPARTICLES  
          The  preparation  of  felodipine loaded polymeric nanoparticles   are    prepared  
according to Solvent displacement / Nanoprecipitation technique.(Bivash Mandal et 
al., 2010,  Suganeswari M et al., 2011 & Srinivas P et al., 2012).  
  A known weight of  felodipine 10 mg, polymers  eudragit L 100, eudragit S 
100 of different  ratios (1:10,1:20,1:30,1:40,1:50,1:60&1:70))  are dissolved  well in 
10 ml of  methanol, forms an organic phase. An aqueous phase which comprises of 
20ml of water containing different concentrations of  stabilizers 1% pluronic F 68 and 
1% polyvinyl alcohol. The organic phase is slowly injected on to the aqueous phase 
under continuous stirring. To achieve nanoprecipitation, an organic solution of the 
polymer is simply added to a non- solvent of the polymer (generally water) with 
which the organic solvent is miscible. Nanoparticles form instantaneously by 
precipitation of the polymer in narrow window of composition, after which the 
organic solvent is removed by evaporation under continuous stirring for 3- 4 hours. 
The plain (drug free) nanoparticles are prepared using the same procedure by omitting 
the drug.(Nepolean R et al.,  2012). 
4. CHARACTERIZATION OF FELODIPINE POLYMERIC  
    NANOPARTICLES 
         The prepared felodipine polymeric nanoparticles are evaluated in terms of drug 
content, entrapment efficiency, particle size and polydispersity index, zetapotential 
measurement, in vitro drug release studies and kinetics of  drug release. 
a. Determination of drug content  
         The total amount of drug content present in the prepared formulation is 
evaluated using UV- spectrophotometric analysis. A known weight  1 mg equivalent 
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of felodipine is taken from the  polymeric nanosuspension  which is dissolved in 1ml 
of methanol  and is suitably diluted  to 100 ml  to make (10µg/ml) concentration  
using the buffer solution. The absorbance of the above prepared solution is 
determined  at 362nm UV – visible spectrometer. The total drug content can be 
calculated from the standard curve using the formula given below, 
                             Sample absorbance 
Drug content= ------------------------------------------x 100 
                            Standard absorbance 
 
(Sanjay singh et al., 2009). 
b. Determination  of   Entrapment efficiency 
                 The amount of felodipine encapsulated in the  polymeric nanoparticles  
(entrapped drug) are separated  from  the aqueous   medium  by  ultracentrifugation 
(Eppendorf Centrifuge, 5417R, Germany) at 14,000 rpm for 90 min at 4˚C. Then, the 
sample is taken from the separated supernatant liquid and diluted suitably using  the  
buffer solution and the amount of  free  drug  present  is  determined  by  measuring  
the  absorbance  at  362nm  by UV- spectrophotometer. The amount of Felodipine 
encapsulated in polymeric nanoparticle formulation  is   calculated from the difference 
between  the total drug content and the amount of unentraped drug remaining in the 
aqueous medium. The entrapment efficiency (EE) can be calculated  as follows  
                                                 Drug content – unentraped drug 
Entrapment efficiency =   ----------------------------------------------  x 100 
                                                         Drug content 
 
(Abdul Hasan Sathali  A and Gopinath M et al., 2013). 
c. Determination of Particle Size and Zeta potential  
        The particle size, polydispersity index (PI) & zeta potential of felodipine loaded 
polymeric nanoparticulate suspension are studied by dynamic light scattering 
CHAPTER IX                                                              EXPERIMENTAL PROTOCOL	
 
Felodipine Polymeric Nanoparticles Reg.No.261211303          	 Page	86	
 
technique using a Zetasizer 3000 (Malvern Instruments, UK). It yields the mean 
particle diameter (average diameter Z-AVE) and  the width of particle size distribution 
(polydispersity index,PI). The aqueous nanoparticulate suspension is diluted with 
distilled water before analysis and the sample is scattered at  a fixed angle of 90ᵒ. Zeta 
potential is highly useful for the assessment of the physical stability of colloidal 
dispersions. The particle surface charge  is quantified as zeta potential.(Rezaei 
Mokarram A et al., 2010 & Srinivas P et al., 2012). 
d. in vitro  drug release studies 
The in vitro drug release studies of felodipine loaded polymeric nansuspension 
is  evaluated using dialysis bag method by diffusion mechanism. The nanoparticulate 
suspension  equivalent to 1 mg of  felodipine  is placed in a dialysis bag and sealed at 
both the ends. The dialysis bag which contains the formulation which acts as the 
donor compartment and a beaker containing the buffer solution acts as a receptor 
compartment is stirred at a minimum speed and maintained at 37˚C±2˚C. 
Initially, the dialysis bag is kept in 0.1N hydrochloric acid with 0.1%w/v SLS 
acid buffer for a period of 2 hours and then it is placed at pH 6.5 with 0.1%w/v SLS 
phosphate buffer for the next 10 hours. Aliquots of samples 5ml are withdrawn at 
subsequent time intervals and the same amount must be replaced on to the diffusion 
medium with the buffer solution to maintain the sink condition. The samples are 
withdrawn at an interval of 15 minutes for the first 2 hours and 30 minutes interval for 
the next10 hours. Finally, the amount of felodipine dissolved is determined by 
measuring the absorbance at 362nm by UV- spectrophotometer. And, the experiment 
is performed in triplicate.(Mishra B et al., 2010 & Umar faruksha A et al., 2013). 
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e. Kinetics of drug release studies 
         In order to understand the kinetic and mechanism of drug release, the result of in 
vitro drug release study of nanoparticles are fitted with various kinetic equation like  
1. Zero order( cumulative %release  vs  time). 
2. First order( log % drug remaining  vs  time). 
3. Higuchi’s model ( cumulative %drug release vs square root of time). 
4. Hixon-Crowell cube root law. 
5. Korsmeyer-peppas model. 
1. The  zero  order  equation describes  the  systems  where  the drug  release  rate  is 
independent of its concentration. 
C = k0t  
Where C is the concentration of the drug at time (t) and k0 is the zero-order 
release rate constant. 
2. The first order Equation  describes the release from a system where the release 
rate is concentration dependent. 
log C = log C0 - kt / 2.303  
Where C is the concentration of the drug at time (t), C0 is the initial 
concentration of the drug and k is the first-order release rate constant. 
3. Higuchi described the release of drugs from porous, insoluble matrix as a square 
root of time dependent process based on Fickian diffusion as shown below 
Q = kt1/2                
Where Q is the amount of drug released in time t. 
4. The Hixson-Crowell cube root law  describes the release from systems where 
there is a change in surface area and diameter of particles. 
W01/3 – Wt1/3 = κt   
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Where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt 
is the remaining amount of drug in the pharmaceutical dosage form at time t, and κ is 
the constant incorporating the surface-volume relationship. 
5. Korsmeyer – Peppas model describes the fraction of drug  release relates 
exponentially with  respect to time. 
Mt/M∞ =Ktn     
Where Mt/M∞ is  a fraction of drug released at timt t, k is the release rate 
constant and n is the  release exponent.(Abdul Hasan Sathali  A  and Gopinath M et 
al., 2013  & Bivash Mandal et al., 2010).  
f. Selection and evaluation of best formulation 
 The best formulations are selected based on the results obtained from particle 
size analysis, entrapment efficiency, in vitro drug release studies and drug release 
kinetics.  
i. Lyophilization of nanosuspensions  
Felodipine nanosuspensions are lyophilized by using freeze dryer (Lyodel-
Delvac Pumps Pvt. Ltd, USA) to enhance the chemical stability of nanosuspension. 
The freshly prepared nanosuspensions are lyophilized with cryoprotective agent 
(mannitol). Briefly, Felodipine nanosuspensions are rapidly cooled down to -500C for 
2 hours followed by primary drying at I.03 mbar and secondary drying at 0.001 mbar. 
Entrapment efficiency and In vitro drug release of the lyophilized polymeric 
nanoparticles (F7 EL 100 with 1% pluronic F68) is then compared with that of pure 
drug (Felodipine). (Rainer H Muller et al., 2008). 
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ii. Infrared spectroscopic analysis 
          Infrared spectrum(IR)  analysis is carried out for the selected best formulation 
to find out the interactions between the drug  and  excipients used as per the procedure 
mentioned on  drug polymer interaction studies 2(a). 
iii. Solubility measurement studies 
         The solubility of the best formulations of felodipine loaded polymeric 
nanoparticulate suspension and pure drug  in distilled water and  phosphate buffer  pH 
6.5 with 0.1% w/v SLS is carried out in a mechanical shaker apparatus. A known 
weight equivalent to 1mg of felodipine pure drug and nanosuspension are  separately 
introduced in to the 250 ml stoppered conical flasks containing 10 ml of the  
respective solvents. The sealed flasks are agitated on a mechanical shaker for 24 hrs. 
An aliquot is filtered and the filterate is suitably diluted and analysed on a UV-
spectrophotometer.(Rezaei Mokarram A et al., 2010 & Kathleen Dillen et al., 2006). 
iv. Morphology of Polymeric Nanoparticles by SEM analysis 
         The morphology of the felodipine polymeric nanoparticulate suspension is 
studied using scanning electron microscopy (SEM) (S-4800, Hitachi  Technologies 
Corporation, Japan). Prior to examination, the sample is mounted onto metal stubs 
using a double sided adhesive tape and sputtered with a thin layer of gold under 
vaccum. The scanning electron microscope is operated at an acceleration voltage of 
1.5kv.(Yonggang Yang et al., 2011). 
v. Ex vivo intestinal permeability studies  
The experiments are carried out rat intestinal tissue is used to determine the 
drug permeation profile.  
 The three intestinal segments, duodenum, jejunum and ileum using felodipine 
loaded polymeric nanoparticles for each segments. Rats, fasting for 18 – 20 hours is 
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anaesthetized by some ether sprinkled to a piece of cotton wool in a glass container 
equipped with a lid. After making a midline incision in the abdomen, the intestinal 
segments is isolated as follows: duodenum segment of 8 cm is isolated starting from 
the pylorus; jejunum segment of 10 – 15 cm is isolated 25 cm from the pylorus; and 
ileum segments of  10 – 15 cm is isolated 20 cm upwards from caecum. 
The isolated segments is washed with phosphate buffer saline (PBS) pH 7.4 to 
remove any mucous and lumen contents. The contents are removed from segments 
and again washed with pH 7.4 phosphate buffer. One end of the segment is tied with 
suture thread and the best formulation selected felodipine loaded polymeric 
nanosuspension and pure drug (equivalent to 1 mg) are injected separately in three 
parts of the intestinal segments with the help of syringe and other end of intestine is 
tied with the help of suture thread. Then the tied intestinal segments is placed in 250 
ml beaker containing 100 ml of phosphate buffer pH 7.4 with 0.1% SLS continuously 
bubbled with 95% O2 and 5% CO2  with constant stirring at 50 rpm. The temperature 
of medium maintained at 37°C± 2°C.  
The studies are completed in triplicate manner and aliquots sample of (5 ml) 
withdrawn at the intervals of 15, 30, 60, 90 and 120 minutes. The fresh phosphate 
buffer is replaced after every withdrawal to maintain the sink condition. The collected 
samples is analysed by UV Visible spectophotometrer  (Shimadzu UV-1700 pharma 
spec, Japan)  at 362nm. The cumulative amount of drug permeated is plotted against 
















RESULTS AND DISCUSSION 
TABLES & FIGURES 
CHAPTER X                                                                RESULTS AND DISCUSSION 
 
Felodipine Polymeric Nanoparticles Reg.No.261211303          	 Page	91	
 
CHAPTER-X 
RESULTS AND DISCUSSION 
1. PREPARATION AND STANDARD CURVES FOR FELODIPINE 
a. Preparation of calibration medium 
 The calibration medium of distilled water with 0.1% w/v SLS, 0.1N 
hydrochloric acid with 0.1% w/v SLS, phosphate buffer pH6.5 with 0.1% w/v SLS 
and phosphate buffer pH7.4 with 0.1% w/v SLS were prepared as per the Indian 
pharmacopoeia. 
b. Estimation of absorption maximum 
The absorption maximum (max) of felodipine was estimated by scanning the 
(10µg/ml) concentration of the drug solution in UV- region (200- 400nm). The 
obtained spectrum showed the max of 362nm in distilled water with 0.1% w/v SLS, 
0.1N hydrochloric acid with 0.1% w/v SLS, phosphate buffer pH 6.5 with 0.1% w/v 
SLS and phosphate buffer pH7.4 which was shown in the Figure. (20a-20d). 
c. Preparation of standard curves of Felodipine  
The standard curves of felodipine were prepared using distilled water, 0.1N 
hydrochloric acid with 0.1% w/v SLS, phosphate buffer pH 6.5 with 0.1% w/v SLS. 
The absorbance of the solutions (5-25µg/ml) was measured in UV-Spectrophotometer 
at 362nm. The linear correlation coefficient obtained was same for both 0.1N 
hydrochloric acid with 0.1%  w/v SLS and phosphate buffer pH6.5 with 0.1% SLS, 
and it was found to be γ = 0.999. Felodipine obeys the Beer’s law within the 
concentration range of (5-25µg/ml). The standard curves of Felodipine were shown in 
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Table(1A-1D) and Figure(20e-20h).(Sandeep Kumar D et al., 2011, Patel V P et al., 
2011, Hariprasanna R C et al., 2010, Raghavendra Rao N G et al., 2010). 
2. DRUG –POLYMER INTERACTION STUDIES 
a. Infrared spectroscopic analysis 
Infrared spectroscopic analysis  were carried out to confirm the compatibility 
between drug and the polymers used for the preparation of polymeric nanoparticles. 
The infrared studies were performed for pure drug, polymers and physical mixture of 
drug and polymers.  The spectra studied at 4000cm-1 to 400 cm-1 were shown in 
(Figure 21a-21i).  
The IR spectrum of pure drug obtained was compared with the spectra of 
physical mixtures of drug and the polymers showed that there was no shifting of  
functional peaks.     
S.NO CHARACTERISTICS WAVE NUMBER(cm-1) 
1 N-H stretching 3095.85 cm-1 
2 C-H stretching in CH2 2963.93 cm-1 
3 C-H stretching 2902.96 cm-1 
4 C=O stretching 1696.45 cm-1 
5 C=C stretching 1662.69 cm-1 
6 C-N stretching 1363.72 cm-1 
7 C-C stretching 1172.76 cm-1 
8 C-OCH3 stretching 1058.96 cm-1 
9 C-Cl 705.01  cm-1 
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All the major peaks present in the spectrum of pure drug were clearly 
observed in the spectrum of physical mixtures with  negligible changes.  From the 
obtained results, it was concluded   that there was no interactions between the drug 
and excipients. 
3. FORMULATION OF FELODIPINE LOADED POLYMERIC                  
 NANOPARTICLES   
Polymeric nanoparticles were prepared using eudragit L100 and eudragit S100 
by nanoprecipitation technique.  This method developed by Fessi et al.,1992. 
represents an easy and reproducible technique. This method is based on the interfacial 
deposition of a polymer following displacement of a semi polar solvent miscible with 
water from a lipophilic solution.(Bivash Mandal et al., 2010, Ugo Bilati et al., 2005 & 
Snjezana Stolnik et al.,1999).  
All the formulations of felodipine (F1-F28) were prepared using polymers 
(Eudragit L100 & Eudragit S100) at different ratios (1:10,1:20,1:30,1:40,1:50,1:60 & 
1:70) and stabilizers (Pluronic F68 and Polyvinyl alcohol) at concentration of 1%. 
The different polymer ratios and surfactant concentrations were shown in the 
Table(2A-AD).(Swarnali Das et al.,2010). 
The polymeric nanoparticles were prepared by dissolving the polymers 
(Eudragit L100 and Eudragit S100) using an organic solvent (methanol), with or 
without felodipine and the organic phase was introduced drop wise into the  stirred 
surfactant aqueous phase containing  concentration of 1% pluronic F68 and  1% 
polyvinyl alcohol resulting in a colloidal suspension. Instantaneous formation of a 
colloidal suspension occurred as a result of the polymer deposition on the interface 
between the organic phase and water, when partially water miscible organic solvent 
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(methanol) diffused out quickly into the aqueous phase from each transient particle 
intermediate.(Sanjay Singh et al.,2009, Srinivas et al.,2012 & Nepolean R et al.,2012). 
4. CHARACTERIZATION OF FELODIPINE LOADED POLYMERIC        
 NANOPARTICLES 
a. Determination of drug content 
The drug content for all the prepared formulations (F1 to F28)  were found to 
be in the range of 91.08% to 94.82% which was shown in Table(3A-3D). The results 
indicated that there was uniform distribution of drug in all nanoparticle formulations. 
(Sanjay Singh et al., 2009). 
b. Determination of entrapment efficiency 
Polymeric nanoparticle formulations, the impact of polymer and stabilizer 
concentration on entrapment efficiency was considerably significant. The ranges of 
entrapment efficiency of formulations F1-F28 were 29.72% to 63.95% as shown in 
Table(4A-4D) and Figure(22).(Sanjay Singh et al., 2009). 
  The formulations F1-F28, the maximum entrapment efficiency was obtained 
for the formulation F7 eudragit L100 with 1% pluronic F68 was found to be 63.95% 
respectively. It could be attributed to the higher concentration of polymer (1:70) ratio 
in the nanoparticle formulation. The fabrication parameters such as different drug-
polymer ratios and different stabilizers at concentrations were used to achieve the 
highest entrapment of felodipine. 
i. Influence of drug-polymer ratio 
The entrapment efficiency of felodipine loaded eudragit L100 and eudragit 
S100 nanoparticles was greatly influenced by the drug- polymer ratios. The results 
were shown in Table(4A-4D) and Figure(22).(Peng et al., 2007). 
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Formulations F1-F7 prepared using different ratios of polymer (Eudragit 
L100) (1:10,1:20,1:30,1:40,1:50,1:60&1:70) containing 1% pluronic F68  as stabilizer 
showed the entrapment efficiency of 29.72%, 30.05%, 31.90%, 33.65%, 45.66%, 
57.86% & 63.95% respectively. The entrapment efficiency was increased in the 
order of F2<F1<F3<F4<F5<F6<F7.  
Formulations F8-F14 prepared using different ratios of polymer (Eudragit 
L100) (1:10,1:20,1:30,1:40,1:50,1:60&1:70) containing 1% polyvinyl alcohol as 
stabilizer showed the entrapment efficiency of 30.81%, 31.46%, 34.99%, 39.42%, 
43.37%, 51.07% & 59.38% respectively. The entrapment efficiency was increased in 
the order of F8<F9<F10< F11<F12<F13<F14.  
Formulations F15-F21 prepared using different ratios of polymer (Eudragit 
S100) (1:10,1:20,1:30,1:40,1:50,1:60&1:70) containing 1% pluronic F68 as stabilizer 
showed the entrapment efficiency of 31.55%, 32.02%, 33.05%, 35.75%, 44.77%, 
50.22% & 58.02% respectively. The entrapment efficiency was increased in the 
order of F15<F16< F17<F18<F19<F20<F21.  
Formulations F22-F28 prepared using different ratios of polymer (Eudragit 
S100) (1:10,1:20,1:30,1:40,1:50,1:60&1:70) containing 1% polyvinyl alcohol as 
stabilizer showed the entrapment efficiency of 30.45%, 31.90%, 34.12%, 34.28%, 
40.28%, 46.02% & 53.29% respectively. The entrapment efficiency was increased in 
the order of F22<F23<F24<F25<F26<F27<F28.  
 From the results it was observed the felodipine nanoparticle formulations 
prepared with 1:70 ratio of eudragit L100 showed the higher entrapment than the 
other formulations prepared with (1:10,1:20,1:30,1:40,1:50,&1:60) ratios of  eudragit 
L100. The high entrapment efficiency of felodipine was believed to be due to its poor 
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aqueous solubility, high affinity of drug and polymer affinity in the same organic 
solvent (methanol) and increased polymer ratio. This is increase in polymer 
concentration in organic phase enhanced the drug entrapment due to increase in 
organic phase viscosity, which increased the diffusional resistance to drug molecules 
from organic phase to aqueous phase, thereby entrapping more drug in the polymeric 
nanoparticles.(Poovi G et al.,2011, Swarnali Das et al., 2010 & Annick Ludwig et al., 
2006).  
ii. Influence of stabilizer concentration 
The effect of stabilizers (Pluronic F68 & Polyvinyl alcohol) on the entrapment 
efficiency   of felodipine loaded eudragit L100 and eudragit S100 nanoparticles were 
investigated. The results were shown in the Table(4A-4D) and Figure(22). 
Felodipine loaded polymeric nanoparticles prepared with pluronic F68 showed better 
entrapment than those prepared with polyvinyl alcohol.   
 Felodipine loaded polymeric nanoparticles prepared with pluronic F68 showed 
better entrapment than those prepared with polyvinyl alcohol.(Anilkumar J Shinde et 
al., 2011). 
c. Determination of particle size, polydispersity index & zeta potential   
The particle size diameter(Z-AVE), polydispersity index(PI) and zeta potential 
of the prepared nanoparticulate suspension were  studied by dynamic light scattering  
microscopy.(Annick Ludwig et al.,2006).   
The particle size in the range of less than 400nm were preferred in 
pharmaceutical process development. The mean particle diameters of high entrapment 
efficiency of  the formulations (F7,F14,F21&F28) was found to be in the range of 
192.4nm, 238.7nm, 210.3nm & 298.4nm as shown in Table(5A&5B) & (Figure23a-
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23d).   The formulations in terms of drug / polymer ratios, surfactant concentration as 
well as the volume of external phase resulted in significant differences in  particle 
size.(Jawahar N et al.,2009). 
i). Influence of drug –polymer ratio on particle size: 
The influence of drug- polymer ratio (1:70) of felodipine loaded eudragit L100 
and  eudragit S100 nanoparticles on the particle size was investigated. The results 
were   shown in Table.(5A&5B)&(Figure23a-23d).  
Formulations F7, F14 prepared using  polymer (Eudragit L 100) (1:70)  
containing 1% pluronic F68 & 1% polyvinyl alcohol  as stabilizer showed  the particle 
size of 192.4nm,238.7nm respectively The mean particle size was increased in the 
order of F7 < F14.  
Formulations F21, F28 prepared using  polymer (Eudragit S 100) (1:70)  
containing 1% pluronic F68 & 1% polyvinyl alcohol  as stabilizer showed  the particle 
size of  210.3nm&298.4nm respectively The mean particle size was increased in the 
order of F21 < F28.  
It was concluded that an increase in polymer concentration increased the 
particle size of nanoparticles. i.e., the particle size of felodipine loaded polymeric 
nanoparticles showed a positive relationship with (Eudragit L100 & Eudragit S100) 
concentration. 
This is because, increasing polymer concentration led to increase in the 
viscosity of the organic phase. i.e., high viscous resistance to the shear forces hinder 
the nanoparticle formation. A more viscous organic phase provides a higher mass 
transfer resistance, the diffusion of polymer – solvent phase into the external aqueous 
phase is reduced and larger nanoparticles are formed.(Annick Ludwig et al.,2006).   
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ii). Influence of stabilizers on particle size 
Felodipine loaded polymeric nanoparticles were prepared using two different 
stabilizers (Pluronic F68 & Polyvinyl alcohol) at 1% concentration as shown in 
Table.(5A&5B)&(Figure23a-23d). 
Formulation F7 prepared with 1% pluronic F68 showed the  mean particle size 
of 192.4nm respectively. 
Formulation F14 prepared with 1% polyvinyl alcohol showed the  mean 
particle size of 238.7nm respectively. 
Formulation F21 prepared with 1% pluronic F68 showed the  mean particle 
size of 210.3nm respectively. 
Formulation F28 prepared with 1% polyvinyl alcohol showed the  mean 
particle size of 298.4nm respectively. 
Thus it was concluded that, at high concentration, more  amount of stabilizers 
could be oriented at organic solvent/water interface to reduce efficiently the 
interfacial tension, which resulted in significant increase in the net shear stress at a 
constant energy density during emulsification and promoted the formation of smaller 
emulsion droplets (Anilkumar J Shinde et al., 2010).  
Stabilization of nanoparticles in polymeric nanosuspension  requires a 
stabilizer that binds on to the particle surface.  Pluronic F68 adsorb strongly on to the 
surface of hydrophobic nanoparticles via their hydrophobic polyoxypropylene centre 
block and have been shown to be quite successful in regard to stabilization of 
nanoparticles. 
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Formulations prepared with pluronic F68 (F7 EL 100 & F21 ES 100) showed 
the particle size in the 192.4nm & 210.3nm. Similarly, Formulations prepared with 
polyvinyl alcohol (F14 EL 100 & F28 ES 100) showed the particle size in the 
238.7nm & 298.4nm. Two stabilizers, pluronic F68 and polyvinyl alcohol were tried 
to stabilize the formulation. The average particle size obtained using pluronic F68 was 
lesser than that obtained with polyvinyl alcohol.(Annick Ludwig et al.,2006 & 
Jawahar N et al.,2009). 
Polydispersity Index 
 Polydispersity Index (PI), plays an important role  in the physical stability of 
nanosuspension and should be as low as possible for long term stability. The 
polydispersity index of  high entrapment efficiency of the formulations (F7, F14, F21 
& F28) )  were shown in the Table.(5A&5B)&(Figure23a-23d).  It is a measure of 
dispersion homogeneity and ranges from 0 to 1.Values close to 0 indicates  a 
homogenous dispersion while those greater than 0.3 indicate high heterogeneity. 
The polydispersity index of   formulations (F7&F14)  composed of EL 100 
and ES 100 at concentrations 1% pluronic F68 and 1% polyvinyl alcohol was found to 
be in the range of 0.132 & 0.165.  
The polydispersity index of   formulations (F21&F28)  composed of EL 100 
and ES 100 at concentrations 1% pluronic F68 and 1% polyvinyl alcohol was found to 
be in the range of 0.159 & 0.172.  
All of them exhibited a PI value of less than 0.3,which showed a  relative 
homogenous dispersion.(Kristl B et al., 2002). 
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Zetapotential 
Colloidal stability of the prepared formulations were measured in terms of 
Zeta potential. Zeta potential of felodipine loaded polymeric nanoparticulate 
suspensions were  investigated to study the effect of different polymers and stabilizers 
on surface charge of nanoparticles. The results were shown in the Table(6A-6B) and 
Figure(24a-24d). 
Zeta potential of formulations F7, F14 prepared with EL 100 showed negative 
zeta potential (-19.4mV& -12.1mV). 
Zeta potential of formulations F21, F28 prepared with ES 100 showed 
negative zeta potential (-16.2mV & -10.9mV). 
The zeta potential of the nanoparticles were  found to be negative due to the 
presence of  terminal carboxylic groups of polymers (Eudragit L100 & Eudragit 
S100). High potential values should be achieved in order to  ensure  a high energy 
barrier and favour a good stability. According to Muller, a zeta potential of about -
25mV allows an ideal stabilization of nanoparticles because the repulsive forces 
prevent aggregation upon ageing. For electrostatically stabilized nanosuspension a 
minimum zeta potential of ± 30mV and for combined steric and electrostatic 
stabilization it should be a minimum of ±20mV.(Dianrui Zhang et al., 2012 & 
Philippe Maincent et al.,1998). 
d. Invitro release studies of Felodipine loaded polymeric nanoparticle using            
dialysis membrane.  
The in vitro release of felodipine from the   polymeric nanoparticles was 
studied   in vitro by the dialysis bag diffusion technique. Initially , the release  studies 
was performed at  0.1N hydrochloric acid with 0.1% w/v of SLS for the first 2 hours, 
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and at Phosphate buffer pH6.5 with 0.1% w/v of SLS for the next 10 hours to mimic 
the in vivo condition , since the aim of this study was to administer the nanoparticles 
by the oral route. The dialysis bag retained nanoparticles and allow the diffusion of 
the drug immediately into the receptor compartment. 
The formulations  F1 to F7 prepared using different concentrations (1:10, 
1:20, 1:30, 1:40, 1:50,1:60 & 1:70) of Eudragit L100 with (1%) pluronic F68 
exhibited an initial burst release of 19.67%, 18.03%, 18.91%, 18.42%, 18.50%, 
16.01%, 15.71% at 2hrs & 72.69%, 69.30%, 67.40%, 65.65%, 63.01%, 59.69%, 
56.12% at 12hrs respectively. The cumulative % drug release was decreased in the 
order of F1 > F2> F2 > F2>F5>F6>F7.  
The formulations F8 to F14  prepared using different concentrations (1:10, 
1:20, 1:30, 1:40, 1:50, 1:60 & 1:70) of  Eudragit L100 with 1%   Polyvinyl alcohol 
exhibited an initial burst release of 21.40%, 20.33%, 18.92%, 18.46%, 17.25%, 
16.66%, 15.73% at 2hrs & 74.54%, 72.50%, 68.81%,  66.59%, 63.29%, 60.53%, 
57.36% at 12hrs respectively. The  cumulative % percentage drug release was 
decreased in the order of  F8 > F9> F10 > F11>F12>F13>F14.       
 
The formulations F15 to F21 prepared using different concentrations (1:10, 
1:20, 1:30, 1:40, 1:50, 1:60 & 1:70) of Eudragit S100 with (1%) Pluronic F68 
exhibited an initial burst release of 21.74%, 19.59%, 18.73%, 18.07%, 17.50%, 
15.96%, 16.15% at 2hrs & 75.60%, 73.12%, 70.38%, 66.29%,  65.20%, 60.02%, 
58.21% at 12hrs respectively. The cumulative % drug release was 
decreased.in.the.order.of.F15.>.F16>.F17.>.F18.>.F19>F20>F21.                                                        
. 
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The formulations F22 to F28  prepared using different concentrations (1:10, 
1:20, 1:30, 1:40, 1:50, 1:60 & 1:70) of Eudragit S100 with (1%) Polyvinyl alcohol 
exhibited an initial burst release of 21.56%, 21.22%, 20.06%, 18.91%, 18.10%, 
16.00%, 15.26% at 2hrs & 75.62%, 73.52%, 71.80%, 67.52%, 66.46%, 61.85%, 
58.55% at 12hrs respectively. The cumulative % drug release was 
decreased.in.the.order.of.F22.>.F23>.F24.>.F25.>.F26>F27>F28.                                                        
  The cumulative % drug release for all the prepared formulations (F1-F28) 
results were shown in the Table.(7A-7D) & Figure.(25a-25d). The smaller size 
nanoparticles prepared with lower amount of Eudragit L100 & Eudragit S100 
exhibited higher drug release rate, this might be due to the increased nanoparticle 
surface resulting in larger drug fraction exposed to the dissolution medium and also 
the higher amount of drug loading. The larger size nanoparticles prepared with higher 
amount of Eudragit L100 & Eudragit S100 exhibited lower drug release rates, this 
might due to the decreased nanoparticle surface resulting in smaller drug fraction 
exposed to  the dissolution medium.(Jawahar N et al.,2009). 
A higher burst release was detected with in first two hours  for the 
formulations containing lesser  amount of polymer ratio(1:20) as shown in Table.(7A-
7D) & Figure.(25a-25d). By increasing the polymeric concentration up to  (1:70) 
ratio, the burst release was reduced and a sustained release was obtained for 12 hrs 
due to the entrapment of drug into polymer matrix in the nanoparticles  thus,  
prolonged  the drug release. 
Among the formulations F1-F7, the burst release was decreased & increased in 
the order of F2>F1>F3>F4>F5>F6>F7. 
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Among the formulations F8-F14, the burst release was decreased in the order 
of F8>F9>F10>F11>F12>F13>F14. 
Among the formulations F15-F21, the burst release was decreased in the order 
of F15>F16>F17>F18>F19>F20>F21. 
Among the formulations F22-F28, the burst release was decreased in the order 
of F22>F23>F24>F25>F26>F27>F28. 
 Burst phase occurs due to the adsorption of drug in the polymeric surface 
which was, however followed by hydration   of the nano-matrix which brings about 
an increment in the diffusional path length of molecules and consequently the rate of 
their diffusion becomes lower. Therefore, gaining of controlled release profile and its 
maintenance could be assumed to be dependent upon the relative hydration rate of the 
polymer and integrity of the hydrated matrix. Therefore, superiority of one 
formulation over the other could be established on the basis of higher entrapment 
efficiency, avoidance of burst release, achievement of a controlled release profile and 
its maintenance in a time dependent manner.  Among that, F7 Eudragit L100, 1% 
Pluronic F68 possessing higher entrapment efficiency 63.95% and least burst release 
profile 15.71% than the rest of the formulations.(Mishra B et al., 2010 & Bivash 
Mandal et al., 2010). 
e. Kinetics of drug release 
The results obtained from the in vitro release studies were attempted to fit into 
various mathematical models as follows: 
a) Cumulative percentage drug release Vs time (zero order rate kinetics) 
b) Log cumulative percentage drug remaining Vs time (first order rate 
kinetics) 
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c) Cumulative percentage drug release Vs square root of time (Higuchi 
classical diffusion model) 
d) Cube root of percentage drug remaining Vs time (Hixon Crowell erosion 
equation). 
e) Log cumulative percentage drug release Vs log time (Korsmeyer Peppas 
exponential equation) 
Various plots of zero order, first order, Higuchi matrix, Korsmeyer - Peppas 
and Hixon – Crowell were shown in Figure.(26-30). The regression coefficient (r2) 
and n values were shown in Table.(8A-8D). 
Higuchi describes drug release as a diffusion process based on Fick's law, 
which is square root of time dependent. The amount of drug release from felodipine 
loaded polymeric nanoparticle formulations (F1-F28) showed a linear relationship 
with square root of time. Hence, the drug release rate could be expressed by higuchi 
diffusion model (r2=0.976 to 0.988). The high correlation coefficients were obtained 
for the first order drug  release  kinetics  for  all  the  formulations   ranging   from      
(r2 = 0.975 to 0.991).   
 Different values of n for cylindrical, spherical and slab of geometrices are 
available in the literature. For spheres, values of 0.5, 0.5 < n < 1.0, 1.0 and higher than 
1.0 are related to Fickian diffusion, anomalous, case II transport and super case II 
transport respectively. According to the data presented in the tables, the values of 
exponent n were within 0.5<n which indicated that the drug release mechanism 
followed non- fickian diffusion.(Abdul Hasan Sathali A and Priyanka et al.,2012, 
Annick Ludwig et al., 2006 & Prasanthi. B et al., 2012). 
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f. Selection and evaluation of best formulation 
 From the above results characterization F7 EL 100 with 1% Pluronic F68 
was selected as the best formulation showing, 
  Particle size   :  192.4 nm. 
  Entrapment  efficiency :  63.95% 
  In vitro drug release  :  56.12% in 12 hours 
  Release kinetics  :  Closest linearity to first order kinetics. 
i. Lyophilization of nanosuspensions 
  Lyophilization of nanosuspensions to obtain the polymeric 
nanoparticles. 
 Determination of entrapment efficiency and in vitro release 
  The entrapment efficiency the formulation (F7 Eudragit L 100 with 1% 
Pluronic F68) containing pluronic F68 as stabilizer showed higher entrapment 
efficiency. These might be due lyophilized polymeric nanoparticles in entrapment 
efficiency in 62.82%. Due to high entrapment, drug release from polymeric 
nanoparticles was sustained. According to these drug release profile in 55.37% in 12 
hours. It was found that cumulative percentage drug release of F7 EL 100 formulation 
were increased due to particle size reduction as compared to pure drug were shown in 
the Table.(7E) & Figure.(25e). 
ii. Infra red spectrum analysis 
               IR spectrum of the best formulation (F7 EL 100 with 1% Pluronic F68) was 
recorded and shown in the Figure.(31). Pure drug (Felodipine) showed its 
characteristic peaks at 3095.85,2963.93,2902.96, 1696.45, 1662.69, 1363.72, 1172.76, 
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1058.96, 705.01 cm-1. The IR spectrum of pure drug obtained was compared with the 
spectra of best formulations showed that there was no shifting of functional peaks.  All 
the major peaks present in the spectrum of pure drug were clearly observed in the 
spectrum   of best formulations without any   significant changes.  From the obtained 
results, it was concluded that there was no interactions between the drug and the 
excipients used in the formulation.(Abdul Hasan Sathali A and Priyanka K et 
al.,2012). 
iii. Solubility measurement studies 
The solubility measurement study was conducted  for the best formulation (F7 
EL 100 with 1% Pluronic F68) as well as the pure drug using distilled water and 
phosphate buffer pH 6.5 with 0.1% SLS as shown in Table.(9) & Figure.(32a&32b). 
The solubility of formulation F7 EL 100 with 1% pluronic F68 & pure drug in 
distilled water were 117.23µg/ml and 29.91µg/ml respectively.   The solubility of 
formulation F7 EL 100 with 1% pluronic F68 & pure drug in phosphate buffer pH6.5 
with 0.1% SLS were 260.58µg/ml and 43.89µg/ml respectively.   It was observed that 
the  best formulations  showed highest solubility compared to the pure drug in both 
distilled water and phosphate buffer pH6.5 with 0.1% SLS were shown in  Table.(9)  
& Figure.(32a&32b) (Dianrui Zhang et al., 2012, Arunkumar N et al., 2009 & Abdul 
Hasan Sathali A and Gopinath M et al.,2013). 
iv. Morphology of polymeric nanoparticles by SEM analysis 
  In order to characterize the morphology of nanoparticle formulations 
SEM analysis was performed. The SEM Photograph of the selected best formulations 
F7(Felodipine+Eudragit L100+1% Pluronic F68) were shown in Figure.(33).The  
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results indicated that the nanoparticles are spherical in shape and below 1µm in size. 
(Julijana Kristl et al.,2009 & Abdul Hasan Sathali A and Priyanka K et al.,2012). 
v. Ex vivo  intestinal permeability studies  
  The results were shown in Table.(10A -10C) & Figure.(34a - 34c). 
In the duodenum region of the intestinal segment, the cumulative amount of drug 
permeated for pure drug solution was about 0.22 mg and the polymeric nanoparticle 
formulation had the permeability of about 0.85 mg (F7) at the end of 2 hrs. 
Similarly in the jejunum region also, the cumulative amount of drug 
permeated for pure drug solution was 0.25 mg and for the polymeric nanoparticle 
formulations had the permeability of 0.89 mg (F7) at the end of 2 hrs. The same type 
of results was also obtained from the ileum region of rat intestine. The pure drug 
solution had the cumulative amount of drug permeability of 0.23 mg and the solid 
lipid nanoparticle formulations had the permeability of 0.87 mg (F7) at the end of 2 
hrs.The intestinal permeability was found to be increase in the  F7 EL 100 with 1% 
Pluronic F68 > Pure drug. 
From the results, it was observed that the nanoparticle formulations showed 
better permeability than the pure drug solution.  
(Abdul Hasan Sathali A and Nisha et al.,2013). 
TABLE 1A: CALIBRATION CURVE OF FELODIPINE USING DISTILLED 
WATER WITH 0.1% SLS 
 
   n =3*                                                                        = 0.999564 
TABLE 1B: CALIBRATION CURVE OF FELODIPINE USING 0.1N 
HYDROCHLORIC ACID WITH 0.1% SLS 
 
   n =3*                                                                                    = 0.999570 
 
   
 S.NO 





      
     1 
                    
                      5 0.080±0.0015 
 
     2 
 
                     10 0.181±0.0015 
 
     3 
 
                     15 0.265±0.0020 
 
     4 
 
                     20 0.361±0.0035 
 
     5 
 
                     25 0.448±0.0026 
   
 S.NO 





      
     1 
                    
                      5 0.087±0.0015 
 
     2 
 
                     10 0.186±0.0020 
 
     3 
 
                     15 0.270±0.0025 
 
     4 
 
                     20 0.363±0.0045 
 
     5 
 
                     25 0.456±0.0041 
TABLE 1C: CALIBRATION CURVE OF FELODIPINE USING PHOSPHATE 
BUFFER pH 6.5 WITH 0.1% SLS 
 
    n =3*                                                                                   = 0.999459 
TABLE 1D: CALIBRATION CURVE OF FELODIPINE USING PHOSPHATE 
BUFFER pH 7.4 WITH 0.1% SLS 
 
 n =3*                                                                          = 0.999576 
          
   
 S.NO 





      
     1 
                    
                      5 0.086±0.0017 
 
     2 
 
                     10 0.187±0.0015 
 
     3 
 
                     15 0.270±0.0025 
 
     4 
 
                     20 0.364±0.0015 
 
     5 
 
                     25 0.447±0.0026 
   
 S.NO 





      
     1 
                    
                      5 0.079±0.0015 
 
     2 
 
                     10 0.176±0.0015 
 
     3 
 
                     15 0.269±0.0025 
 
     4 
 
                     20 0.368±0.0026 
 
     5 
 
                     25 0.450±0.0025 
TABLE 2A:COMPOSITION OF FELODIPINE LOADED EUDRAGIT L 100 NANOPARTICLES CONTAINING                                          















F1 1:10 10mg 100mg 1% - 
F2 1:20 10mg 200mg 1% - 
F3 1:30 10mg 300mg 1% - 
F4 1:40 10mg 400mg 1% - 
F5 1:50 10mg 500mg 1% - 
F6 1:60 10mg 600mg 1% - 




TABLE 2B: COMPOSITION OF FELODIPINE LOADED EUDRAGIT L 100 NANOPARTICLES CONTAINING                                          















F8 1:10 10mg 100mg - 1% 
F9 1:20 10mg 200mg - 1% 
F10 1:30 10mg 300mg - 1% 
F11 1:40 10mg 400mg - 1% 
F12 1:50 10mg 500mg - 1% 
F13 1:60 10mg 600mg - 1% 




TABLE 2C: COMPOSITION OF FELODIPINE LOADED EUDRAGIT S 100 NANOPARTICLES CONTAINING                                          















F15 1:10 10mg 100mg 1% - 
F16 1:20 10mg 200mg 1% - 
F17 1:30 10mg 300mg 1% - 
F18 1:40 10mg 400mg 1% - 
F19 1:50 10mg 500mg 1% - 
F20 1:60 10mg 600mg 1% - 




TABLE 2D: COMPOSITION OF FELODIPINE LOADED EUDRAGIT S 100 NANOPARTICLES CONTAINING                                   















F22 1:10 10mg 100mg - 1% 
F23 1:20 10mg 200mg - 1% 
F24 1:30 10mg 300mg - 1% 
F25 1:40 10mg 400mg - 1% 
F26 1:50 10mg 500mg - 1% 
F27 1:60 10mg 600mg - 1% 
F28 1:70 10mg 700mg - 1% 
 
 
TABLE 3A: DRUG CONTENT OF FELODIPINE LOADED  EUDRAGIT L 
100 NANOPARTICLES USING  1% PLURONIC F 68 
S.NO FORMULATION CODE DRUG CONTENT  (%) ± SD* 
1 F1 93.58%±2.14 
2 F2 91.08%±0.81 
3 F3 92.68%±1.11 
4 F4 93.75%±1.63 
5 F5 92.50%±1.60 
6 F6 93.04%±2.44 
7 F7 93.04%±1.60 
    n=3* 
 
TABLE 3B: DRUG CONTENT OF FELODIPINE LOADED  EUDRAGIT L 
100 NANOPARTICLES USING  1% POLYVINYL ALCOHOL 
S.NO FORMULATION CODE DRUG CONTENT  (%) ± SD* 
1 F8 93.04%±1.92 
2 F9 92.33%±2.16 
3 F10 93.22%±2.16 
4 F11 91.26%±1.34 
5 F12 91.08%±2.94 
6 F13 91.79%±1.63 
7 F14 93.04%±2.14 
n=3* 
 
TABLE 3C: DRUG CONTENT OF FELODIPINE LOADED  EUDRAGIT S 
100 NANOPARTICLES USING  1% PLURONIC F 68 
S.NO FORMULATION CODE DRUG CONTENT  (%) ± SD* 
1 F15 94.82% ±1.11 
2 F16 92.86% ±3.47 
3 F17 94.82% ±2.69 
4 F18 92.15% ±2.22 
5 F19 93.22% ±2.41 
6 F20 93.04% ±2.44 
7 F21 91.26% ±1.11 
n=3* 
 
TABLE 3D: DRUG CONTENT OF FELODIPINE LOADED  EUDRAGIT S 
100 NANOPARTICLES USING  1% POLYVINYL ALCOHOL 
S.NO FORMULATION CODE DRUG CONTENT  (%) ± SD* 
1 F22 94.82% ±2.16 
2 F23 94.29% ±3.48 
3 F24 93.93% ±1.72 
4 F25 93.58% ±2.14 
5 F26 92.51% ±2.14 
6 F27 92.15% ±1.71 
7 F28 92.15% ±1.71 
n=3* 
 
TABLE 4A: ENTRAPMENT EFFICIENCY OF FELODIPINE LOADED  
EUDRAGIT L 100 NANOPARTICLES USING  1% PLURONIC F 68 
S.NO FORMULATION CODE ENTRAPMENT 
EFFICIFICENCY(%) ± SD* 
1 F1 30.05±3.53 
2 F2 29.72±3.27 
3 F3 31.90±3.20 
4 F4 33.65±3.60 
5 F5 45.66±1.05 
6 F6 57.86±3.07 
7 F7 63.95±3.50 
   n=3* 
 
TABLE 4B: ENTRAPMENT EFFICIENCY OF FELODIPINE LOADED  
EUDRAGIT L 100 NANOPARTICLES USING  1% POLYVINYL ALCOHOL 
S.NO FORMULATION CODE ENTRAPMENT 
EFFICIFICENCY(%) ± SD* 
1 F8 30.81±2.88 
2 F9 31.46±0.58 
3 F10 34.99±0.63 
4 F11 39.42±3.31 
5 F12 43.37±3.82 
6 F13 51.07±3.33 
7 F14 59.38±1.34 
   n=3* 
 
TABLE 4C: ENTRAPMENT EFFICIENCY OF FELODIPINE LOADED  
EUDRAGIT S 100 NANOPARTICLES USING  1% PLURONIC F 68 
S.NO FORMULATION CODE ENTRAPMENT 
EFFICIFICENCY(%) ± SD* 
1 F15 31.55±3.63 
2 F16 32.02±0.82 
3 F17 33.05±1.38 
4 F18 35.75±2.27 
5 F19 44.77±2.07 
6 F20 50.22±2.22 
7 F21 58.02±2.24 
    n=3* 
 
TABLE 4D: ENTRAPMENT EFFICIENCY OF FELODIPINE LOADED  
EUDRAGIT S 100 NANOPARTICLES USING  1% POLYVINYL ALCOHOL 
S.NO FORMULATION CODE ENTRAPMENT  
EFFICIFICENCY(%) ± SD* 
1 F22 30.45±0.15 
2 F23 31.90±1.72 
3 F24 34.12±2.89 
4 F25 34.28±2.48 
5 F26 40.48±1.51 
6 F27 46.02±2.26 
7 F28 54.47±1.24 
    n=3* 
  
TABLE 5A: PARTICLE  SIZE  OF   FELODIPINE   LOADED   EUDRAGIT L 
100  NANOPARTICLES CONTAINING 1%  PLURONIC F68 & 1% 







1. F7 192.4 0.132 







TABLE 5B: PARTICLE  SIZE  OF   FELODIPINE   LOADED   EUDRAGIT S 
100  NANOPARTICLES CONTAINING 1%  PLURONIC F68 & 1% 







1. F21 210.3 0.159 








TABLE 6A: ZETA POTENTIAL OF FELODIPINE  LOADED  EUDRAGIT L 
100 NANOPARTICLES CONTAINING 1%  PLURONIC F68 & 1% 







1. F7 -19.4 







TABLE 6B: ZETA POTENTIAL OF FELODIPINE  LOADED  EUDRAGIT S 
100 NANOPARTICLES CONTAINING 1%  PLURONIC F68 & 1% 







1. F21 -16.2 







TABLE 7A: COMPARISON OF IN VITRO RELEASE OF FELODIPINE LOADED EUDRAGIT 







CUMULATIVE % DRUG RELEASE 
F1         
EL 100 
F2         
EL 100 
F3         
EL 100 
F4         
EL 100 
F5         
EL 100 
F6         
EL 100 
F7         
EL 100 
1.2 
0.25 5.17±0.83 5.17±0.83 4.99±0.54 4.99±0.54 4.99±0.54 4.99±0.54 4.62±0.31 
0.50 6.52±0.81 7.61±0.86 6.69±0.85 6.51±1.15 6.51±0.86 5.97±0.86 6.31±0.56 
0.75 9.20±1.16 9.44±1.16 8.84±1.69 9.74±1.19 9.19±1.44 7.71±1.51 8.80±1.13 
1.00 12.73±0.91 11.88±0.94 12.35±1.51 13.11±1.55 12.17±1.38 9.89±1.51 10.49±1.47
1.50 15.68±1.47 15.34±1.15 15.83±0.51 15.54±2.37 14.92±0.99 12.71±1.03 12.42±1.25
2.00 19.67±0.81 18.03±1.12 18.91±0.82 18.42±1.60 18.50±0.98 16.01±0.42 15.71±0.49
6.5 
2.50 25.56±0.70 23.83±0.87 25.11±1.70 24.27±1.56 24.45±1.59 21.72±0.94 21.09±1.10
3.00 27.36±1.18 25.45±0.54 26.74±1.09 25.70±1.87 25.70±1.61 22.80±0.91 21.97±0.91
3.50 29.43±1.01 27.70±1.14 28.45±0.45 27.20±1.77 28.13±0.98 24.67±1.73 23.44±1.25
4.00 31.59±1.85 29.86±1.22 30.42±0.62 29.13±1.24 29.55±1.51 26.62±1.24 24.97±1.14
4.50 33.48±2.52 31.75±1.01 32.66±0.88 31.15±0.90 31.03±0.99 28.47±1.40 26.94±1.18
5.00 35.63±2.19 34.64±1.53 34.99±1.38 33.43±1.51 32.56±0.99 30.02±1.14 28.44±0.89
5.50 37.85±1.91 36.35±1.55 36.86±1.19 35.44±1.45 34.89±1.14 31.81±1.24 30.36±1.22
6.00 39.98±1.43 38.30±1.57 39.16±1.24 37.71±1.46 37.13±0.67 33.49±1.27 31.81±1.23
6.50 43.48±1.44 40.87±2.20 41.36±1.55 39.69±1.17 39.27±1.09 35.03±1.52 33.48±1.27
7.00 46.01±2.27 43.53±2.57 43.08±1.65 41.36±1.12 41.48±1.40 36.62±1.26 35.58±1.06
7.50 48.80±2.04 45.74±2.42 45.78±2.02 43.82±1.46 43.02±1.15 38.81±1.00 37.38±1.36
8.00 51.31±2.37 48.56±2.79 48.00±2.41 45.99±1.26 44.98±1.18 41.08±1.04 39.61±1.11
8.50 54.28±2.14 51.47±2.67 50.11±2.50 48.23±1.10 46.98±1.22 42.86±1.17 41.36±1.19
9.00 56.77±1.90 53.37±3.06 51.91±1.15 50.72±1.32 49.04±1.25 45.44±1.19 43.15±1.45
9.50 59.34±1.65 56.23±2.74 54.48±1.72 53.10±1.33 51.35±1.59 47.53±0.78 44.81±1.25
10.00 61.96±1.42 58.80±2.58 56.94±1.80 55.17±1.64 53.53±1.65 49.88±1.63 47.24±1.26
10.50 64.47±1.42 61.25±2.64 59.09±1.63 57.47±1.62 55.95±1.50 52.28±1.97 49.38±1.30
11.00 67.03±1.42 63.20±3.15 61.85±2.16 59.83±1.67 58.07±1.75 54.56±2.03 51.57±1.31
11.50 69.65±1.12 66.66±2.88 64.68±2.22 62.43±1.86 60.42±1.81 57.28±1.78 53.82±1.35







TABLE 7B: COMPARISON OF IN VITRO RELEASE OF FELODIPINE LOADED EUDRAGIT L 







CUMULATIVE % DRUG RELEASE 
F8         
EL 100 
F9         
EL 100 
F10        
EL 100 
F11        
EL 100 
F12        
EL 100 
F13        
EL 100 
F14        
EL 100 
1.2 
0.25 5.90±0.31 5.53±0.54 5.53±0.54 5.17±0.31 4.62±0.31 4.62±0.31 4.62±0.31 
0.50 8.38±0.84 8.00±0.57 8.00±1.12 7.43±1.09 6.31±0.56 6.31±0.54 6.31±0.56 
0.75 11.52±0.89 10.75±0.88 10.39±0.91 9.98±0.60 8.62±1.17 8.44±0.85 8.44±0.86 
1.00 15.15±1.23 14.17±0.92 13.24±0.62 12.81±0.38 11.03±1.47 10.84±0.58 10.84±0.98
1.50 18.22±0.96 17.30±0.85 15.85±0.95 15.40±0.59 13.72±1.42 13.34±0.68 12.97±0.65
2.00 21.40±0.70 20.33±0.78 18.92±0.69 18.46±1.13 17.25±1.34 16.66±0.79 15.73±0.68
6.5 
2.50 28.36±1.21 27.27±1.20 25.30±1.12 24.90±1.08 22.60±1.92 22.14±1.11 21.15±0.91
3.00 29.82±1.37 28.56±1.22 26.75±0.86 26.17±1.08 23.84±1.94 23.76±1.45 22.40±0.92
3.50 32.27±1.19 30.08±1.22 28.45±1.13 27.51±1.08 25.69±1.96 25.26±1.65 24.07±1.10
4.00 34.28±1.39 32.60±1.79 30.41±1.15 29.63±0.78 27.62±2.49 27.21±1.20 25.63±0.94
4.50 36.55±1.61 35.23±1.83 32.45±1.16 31.67±0.77 29.27±2.33 28.49±1.11 27.26±1.27
5.00 38.55±1.45 37.22±1.61 34.77±0.91 34.34±1.31 31.16±2.05 30.19±0.82 28.95±1.15
5.50 40.25±1.47 39.29±1.85 36.62±0.70 36.01±1.33 33.32±2.06 32.14±1.12 30.89±1.31
6.00 42.38±1.82 41.07±1.96 38.90±1.21 37.93±1.09 35.19±1.97 34.17±1.11 32.54±1.83
6.50 44.95±2.02 43.27±1.79 40.90±2.09 40.09±1.22 37.12±2.29 36.27±1.40 34.24±1.38
7.00 47.43±2.07 46.29±0.90 43.70±1.87 42.33±1.42 39.30±2.00 38.26±1.16 36.37±1.58
7.50 49.81±1.96 48.86±1.22 45.86±1.64 44.64±1.67 41.37±2.27 39.94±0.78 38.38±1.43
8.00 52.26±1.84 51.33±0.94 48.46±1.73 46.66±1.71 43.32±1.83 42.41±0.80 40.09±1.64
8.50 55.34±1.71 53.87±0.96 50.96±1.89 49.10±1.98 45.70±1.97 44.59±0.63 42.59±1.67
9.00 57.97±2.09 56.49±1.45 53.35±1.84 51.25±2.03 47.78±2.04 46.65±1.13 44.61±1.71
9.50 60.85±2.09 59.00±0.97 55.80±2.20 53.63±2.37 50.10±1.99 49.33±1.17 46.88±1.56
10.00 63.45±1.81 61.57±1.21 58.32±2.05 56.45±2.10 52.49±1.99 51.53±1.64 48.84±1.77
10.50 66.12±1.52 64.20±1.28 61.08±1.97 58.99±1.88 55.31±2.00 53.97±1.54 51.03±1.81
11.00 69.22±1.04 66.91±1.42 63.18±2.31 61.40±1.91 57.85±1.73 56.11±1.26 53.10±2.08
11.50 72.03±0.71 69.67±1.62 65.87±1.81 64.06±1.69 60.45±1.77 58.47±1.47 55.20±2.21





TABLE 7C: COMPARISON OF IN VITRO RELEASE OF FELODIPINE LOADED EUDRAGIT S 







CUMULATIVE % DRUG RELEASE 
F15        
ES 100 
F16        
ES 100 
F17        
ES 100 
F18        
ES 100 
F19        
ES 100 
F20        
ES 100 
F21        
ES 100 
1.2 
0.25 5.90±0.31 5.72±0.31 5.53±0.54 5.53±0.54 5.72±0.31 4.81±0.31 4.62±0.31 
0.50 8.38±0.82 8.55±1.09 8.18±0.85 7.81±0.84 7.28±0.64 6.32±0.56 6.31±0.54 
0.75 11.33±0.84 11.15±1.14 10.40±0.35 9.83±0.85 9.63±1.30 8.45±0.67 8.62±0.64 
1.00 14.96±0.96 13.50±0.73 13.25±0.56 12.11±1.14 12.45±1.24 11.21±0.89 11.21±0.36
1.50 18.20±0.62 16.66±0.65 15.49±1.13 15.21±0.82 14.84±1.24 13.36±0.93 13.54±0.58
2.00 21.74±0.25 19.59±0.54 18.73±0.68 18.07±0.31 17.50±0.84 15.96±0.78 16.15±0.91
6.5 
2.50 29.26±0.53 26.48±1.12 25.09±0.24 24.48±0.43 23.67±1.41 21.43±1.28 21.64±0.84
3.00 31.12±1.03 28.32±1.14 26.72±0.41 25.76±0.46 25.30±1.59 22.68±1.29 22.89±0.42
3.50 33.06±1.54 30.98±1.48 28.99±0.63 27.83±0.58 27.57±1.77 24.54±1.31 24.38±0.71
4.00 35.46±1.45 32.84±1.44 30.80±1.00 30.18±1.09 29.57±1.59 26.29±1.19 25.93±1.02
4.50 37.58±1.51 35.51±0.72 33.06±1.31 31.70±1.13 31.46±1.80 28.68±1.98 27.92±1.03
5.00 39.80±1.18 37.37±0.64 35.22±1.13 33.65±1.33 33.62±1.85 30.43±1.70 29.43±1.21
5.50 41.90±1.16 39.48±0.40 36.92±1.19 36.05±1.56 36.23±1.40 32.24±1.41 31.37±1.52
6.00 43.90±0.69 42.03±0.62 39.40±1.57 38.17±1.45 38.01±1.29 33.93±1.93 33.39±1.74
6.50 46.33±0.70 43.94±1.05 41.43±1.43 40.17±1.69 40.04±1.00 36.05±2.29 35.48±1.65
7.00 49.04±1.40 46.09±1.26 43.52±1.82 42.43±1.57 41.57±1.18 37.87±1.94 37.09±1.60
7.50 51.27±1.35 48.48±1.64 46.23±2.03 44.58±1.81 44.07±1.40 40.12±2.29 39.30±1.62
8.00 54.13±1.35 50.95±2.02 48.85±2.44 46.97±1.69 46.46±1.46 41.88±2.12 41.40±1.66
8.50 56.53±1.68 53.87±1.78 51.36±2.25 49.44±2.06 48.56±1.47 43.88±2.16 43.38±1.69
9.00 59.36±1.19 56.69±2.28 53.95±2.40 51.80±2.41 50.53±1.73 46.30±2.52 45.23±1.47
9.50 61.90±1.21 59.59±2.48 56.25±2.16 54.22±2.19 52.73±1.76 48.25±2.90 47.68±1.27
10.00 64.51±1.51 62.21±2.27 58.78±2.53 56.71±2.34 54.99±1.78 50.23±2.34 49.83±1.28
10.50 67.19±1.29 64.89±1.88 61.94±2.37 58.89±2.20 57.49±2.51 52.45±2.38 51.86±1.14
11.00 69.92±1.63 67.45±1.93 64.44±1.90 61.12±2.16 60.24±2.42 54.73±2.42 53.93±1.46
11.50 72.91±1.37 70.07±1.99 67.38±2.21 63.58±2.22 62.87±2.23 57.43±2.38 56.05±1.30




TABLE 7D: COMPARISON OF IN VITRO RELEASE OF FELODIPINE LOADED EUDRAGIT S 








CUMULATIVE % DRUG RELEASE 
F22         
ES 100 
F23         
ES 100 
F24         
ES 100 
F25         
ES 100 
F26         
ES 100 
F27         
ES 100 
F28         
ES 100 
1.2 
0.25 5.90±0.31 5.90±0.31 5.35±0.31 5.35±0.31 5.35±0.31 4.81±0.31 4.62±0.31 
0.50 8.56±1.09 8.74±0.81 7.44±0.56 7.44±0.53 7.44±0.54 6.87±0.54 6.13±0.32 
0.75 11.52±0.85 11.35±0.86 10.71±0.85 10.53±0.54 10.35±0.66 9.20±1.16 7.88±0.33 
1.00 14.98±1.47 14.98±1.06 13.40±0.70 13.40±0.82 12.66±0.60 11.09±0.92 10.07±0.32 
1.50 17.85±1.21 18.40±0.50 16.93±0.67 16.01±1.13 15.24±0.35 13.05±0.67 12.17±0.87 
2.00 21.56±0.94 21.22±0.27 20.06±0.57 18.91±0.64 18.10±0.37 16.00±0.86 15.26±0.69 
6.5 
2.50 28.51±1.12 28.74±0.57 26.72±0.81 25.28±0.50 24.35±0.73 21.50±0.72 20.36±1.02 
3.00 30.35±1.32 30.23±0.77 28.37±1.46 26.92±0.75 25.80±1.05 23.12±1.20 21.78±1.12 
3.50 33.37±1.82 32.71±0.80 30.46±1.84 28.81±1.64 27.87±0.88 25.37±1.36 23.46±0.98 
4.00 35.05±2.02 34.56±0.81 32.45±1.90 30.79±1.69 29.67±0.58 27.16±1.77 25.21±1.31 
4.50 37.17±1.59 36.85±1.39 35.09±1.93 33.04±2.01 31.53±1.23 28.84±2.07 27.03±1.16 
5.00 39.56±1.81 39.05±1.84 37.28±2.46 34.64±2.19 33.85±1.15 30.96±1.58 28.55±1.18 
5.50 41.85±1.48 41.15±1.82 39.19±2.40 36.48±2.04 35.88±1.44 32.79±1.89 30.32±0.99 
6.00 43.86±1.54 43.33±2.20 41.16±1.84 38.57±2.21 38.18±1.50 34.69±1.43 32.33±1.29 
6.50 46.49±1.67 45.57±2.23 43.75±2.20 40.92±1.86 40.37±2.14 36.65±1.55 33.87±1.61 
7.00 48.84±2.12 48.08±2.14 46.24±1.87 42.79±1.91 42.63±1.93 38.67±1.79 35.63±1.65 
7.50 51.44±1.62 50.49±1.81 48.46±1.67 45.28±2.36 44.79±1.75 40.76±1.93 38.20±1.95 
8.00 53.58±1.59 53.15±1.68 51.10±1.69 47.67±2.12 47.01±1.20 42.92±1.65 40.30±2.06 
8.50 55.77±1.61 56.08±1.65 53.64±1.96 50.31±2.17 49.48±1.83 45.14±1.55 42.09±1.82 
9.00 58.76±1.84 58.55±1.47 56.08±1.76 52.49±1.85 51.47±1.58 47.42±1.61 44.30±1.82 
9.50 60.92±1.66 60.90±1.51 58.58±2.10 54.90±1.64 53.69±1.62 49.77±1.34 46.58±1.61 
10.00 63.67±2.14 63.49±1.46 61.14±2.07 57.38±1.43 56.33±1.73 52.00±1.35 48.92±1.42 
10.50 66.32±1.90 65.96±1.49 63.58±2.11 59.74±1.64 58.68±1.77 54.29±1.72 51.32±1.77 
11.00 69.40±1.72 68.49±1.92 66.26±2.45 61.97±1.41 61.27±1.74 56.63±1.75 53.79±1.70 
11.50 72.38±1.46 71.07±2.12 68.64±2.21 64.80±1.20 63.93±1.54 59.21±1.47 56.14±1.74 
12.00 75.62±1.48 73.52±1.89 71.80±1.70 67.52±1.43 66.46±1.57 61.85±1.59 58.55±1.78 
 TABLE 7E: COMPARISON OF IN VITRO DRUG RELEASE OF PURE DRUG 







CUMULATIVE % DRUG RELEASE 
PURE 
DRUG 
F7 EL 100 + 1% 






0.25 0 0 
0.5 0 0 
0.75 0 0 
1.00 0 0 
1.50 0 0 













2.50 1.42±0.32 11.42±0.64 
3.00 2.60±0.31 14.22±0.28 
3.50 4.40±0.32 17.12±0.86 
4.00 5.72±0.32 20.32±0.36 
4.50 6.54±0.33 22.72±0.25 
5.00 7.58±0.67 25.19±0.05 
5.50 8.83±0.38 27.36±0.53 
6.00 9.76±0.40 29.96±0.81 
6.50 - 32.08±1.17 
7.00 - 34.06±1.35 
7.50 - 36.26±1.29 
8.00 - 38.32±1.01 
8.50 - 40.61±0.87 
9.00 - 42.38±0.81 
9.50 - 44.73±0.61 
10.00 - 46.94±0.30 
10.50 - 49.00±0.37 
11.00 - 51.28±0.08 
11.50 - 53.22±0.27 
12.00 - 55.37±0.55 
              n=3* 
TABLE 8A: KINETICS RELEASE STUDIES OF FELODIPINE  LOADED EUDRAGIT L 100 NANOPARTICLES CONTAINING 






















































0.984 4.182 0.990 -0.026 0.982 17.00 0.995 0.647 0.993 -0.081 
TABLE 8B: KINETICS RELEASE STUDIES OF FELODIPINE  LOADED EUDRAGIT L 100 NANOPARTICLES CONTAINING 






















































0.986 4.327 0.990 -0.027 0.981 17.59 0.995 0.657 0.993 -0.085 
TABLE 8C: KINETICS RELEASE STUDIES OF FELODIPINE  LOADED EUDRAGIT S 100 NANOPARTICLES CONTAINING 






















































0.985 4.397 0.991 -0.028 0.983 17.89 0.996 0.658 0.994 -0.087 
TABLE 8D: KINETICS RELEASE STUDIES OF FELODIPINE  LOADED EUDRAGIT S 100 NANOPARTICLES CONTAINING 






















































0.989 4.411 0.986 -0.028 0.976 17.93 0.993 0.672 0.991 -0.087 
 
TABLE 9: COMPARISON OF SOLUBILITY OF BEST FORMULATION (F7 
EL 100 with 1% PLURONIC F68) WITH PURE DRUG USING DISTILLED 
WATER WITH 0.1% SLS AND PHOSPHATE BUFFER pH 6.5 WITH 0.1% 
SLS 
   n=3* 
 
 
TABLE 10A: COMPARISON OF CUMULATIVE AMOUNT OF DRUG 
PERMEATED ACROSS DUODENUM SEGMENT 
 
TIME(HRS) 




F7 EL 100 + 1% 
PLURONIC F 68 
0.25 0.1036±0.008 0.2105±0.013 
0.50 0.1373±0.008 0.3655±0.042 
1.00 0.1708±0.016 0.5617±0.045 
1.50 0.1991±0.016 0.7298±0.021 
2.00 0.2219±0.011 0.8572±0.011 












PURE DRUG  F7 EL 100 + PLURONIC F 68 
24 hrs 
 
Distilled water  29.91µg/ml±3.218 117.23µg/ml±3.215 
Phosphate buffer 





TABLE 10B: COMPARISON OF CUMULATIVE AMOUNT OF DRUG 
PERMEATED ACROSS JEJUNUM SEGMENT 
 
TIME(HRS) 




F7 EL 100 + 1% 
PLURONIC F 68 
0.25 0.1125±0.010 0.2266±0.026 
0.50 0.1484±0.013 0.4287±0.038 
1.00 0.1874±0.019 0.5916±0.041 
1.50 0.2231±0.011 0.7882±0.055 
2.00 0.2533±0.008 0.8975±0.016 
   n=3* 
 
TABLE 10C: COMPARISON OF CUMULATIVE AMOUNT OF DRUG 
PERMEATED ACROSS ILEUM SEGMENT 
 
TIME(HRS) 




F7 EL 100 + 1% 
PLURONIC F 68 
0.25 0.1071±0.010 0.2194±0.016 
0.50 0.1446±0.014 0.4158±0.050 
1.00 0.1765±0.013 0.5731±0.059 
1.50 0.2065±0.011 0.7517±0.032 
2.00 0.2329±0.011 0.8743±0.013 
   n=3* 
  
FIGURE 20a:  λMAX OF FELODIPINE USING DISTILLED WATER WITH 
0.1% SLS  
 
 
FIGURE 20b: λMAX OF FELODIPINE USING 0.1N HYDROCHLORIC ACID 
WITH 0.1% SLS   
 
FIGURE 20c:  λMAX OF FELODIPINE USING PHOSPHATE BUFFER PH 




FIGURE 20d:  λMAX OF FELODIPINE USING PHOSPHATE BUFFER PH 











FIGURE 20e: CALIBRATION OF FELODIPINE USING DISTILLED WATER 





FIGURE 20f: CALIBRATION OF FELODIPINE USING 0.1N 
HYDROCHLORIC ACID WITH 0.1% SLS   
 
FIGURE 20g: CALIBRATION OF FELODIPINE USING PHOSPHATE 
BUFFER PH 6.5 WITH 0.1% SLS 
 
 

















FIGURE 20h: CALIBRATION OF FELODIPINE USING PHOSPHATE 
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FIGURE 25 a: INVITRO RELEASE STUDIES OF FELODIPINE LOADED 
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FIGURE 25b: INVITRO RELEASE STUDIES OF FELODIPINE LOADED 
EUDRAGIT L100 NANOPARTICLES CONTAINING 1% POLYVINYL 
ALCOHOL AS STABILIZER 
 



































FIGURE 25c: INVITRO RELEASE STUDIES OF FELODIPINE LOADED 







































FIGURE 25d: INVITRO RELEASE STUDIES OF FELODIPINE LOADED 




































FIGURE 25e: COMPARISON OF  IN VITRO DRUG RELEASE PROFILE OF  
   FELODIPINE  NANOPARTICLES (F7 EL 100 + 1% PLURONIC F 68) 
WITH PURE DRUG. 
 
  FIGURE 26a: COMPARISON OF INVITRO ZERO ORDER RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 






FIGURE 26b: COMPARISON OF INVITRO ZERO ORDER RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 




 FIGURE 26c: COMPARISON OF INVITRO ZERO ORDER RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 




 FIGURE 26d: COMPARISON OF INVITRO ZERO ORDER RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 








































FIGURE 27a: COMPARISON OF INVITRO FIRST ORDER RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 
NANOPARTICLES CONTAINING 1% PLURONIC F 68 AS STABILIZER 
 
 




































FIGURE 27b: COMPARISON OF INVITRO FIRST ORDER RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 
NANOPARTICLES CONTAINING 1% POLYVINYL ALCOHOL AS 
STABILIZER 
 FIGURE 27c: COMPARISON OF INVITRO FIRST ORDER RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 
NANOPARTICLES CONTAINING 1% PLURONIC F 68 AS STABILIZER 
 
FIGURE 27d: COMPARISON OF INVITRO FIRST ORDER RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 
NANOPARTICLES CONTAINING 1% POLYVINYL ALCOHOL AS 
STABILIZER 
 
  FIGURE 28a: COMPARISON OF INVITRO HIGUCHI MODEL RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 
NANOPARTICLES CONTAINING 1% PLURONIC F 68 AS STABILIZER 
 
 
 FIGURE 28b: COMPARISON OF INVITRO HIGUCHI MODEL RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 
NANOPARTICLES CONTAINING 1% POLYVINYL ALCOHOL AS 
STABILIZER 
  
FIGURE 28c: COMPARISON OF INVITRO HIGUCHI MODEL RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 




FIGURE 28d: COMPARISON OF INVITRO HIGUCHI MODEL RELEASE 
KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 
NANOPARTICLES CONTAINING 1% POLYVINYL ALCOHOL AS 
STABILIZER 
 
 FIGURE 29a: COMPARISON OF INVITRO HIXSON CROWELL MODEL 
RELEASE KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 




FIGURE 29b: COMPARISON OF INVITRO HIXSON CROWELL MODEL 
RELEASE KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 
NANOPARTICLES CONTAINING 1% POLYVINYL ALCOHOL AS 
STABILIZER 
 
 FIGURE 29c: COMPARISON OF INVITRO HIXSON CROWELL MODEL 
RELEASE KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 
NANOPARTICLES CONTAINING 1% PLURONIC F 68 AS STABILIZER 
 
 
FIGURE 29d: COMPARISON OF INVITRO HIXSON CROWELL MODEL 
RELEASE KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 
NANOPARTICLES CONTAINING 1% POLYVINYL ALCOHOL AS 
STABILIZER 
 
  FIGURE 30a: COMPARISON OF INVITRO KORSMEYER PEPPAS MODEL 
RELEASE KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 





FIGURE 30b: COMPARISON OF INVITRO KORSMEYER PEPPAS MODEL 
RELEASE KINETICS OF FELODIPINE LOADED EUDRAGIT L 100 








FIGURE 30c: COMPARISON OF INVITRO KORSMEYER PEPPAS MODEL 
RELEASE KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 







FIGURE 30d: COMPARISON OF INVITRO KORSMEYER PEPPAS MODEL 
RELEASE KINETICS OF FELODIPINE LOADED EUDRAGIT S 100 






















































































































FIGURE 34a: COMPARISON OF CUMULATIVE AMOUNT OF DRUG 




FIGURE 34b: COMPARISON OF CUMULATIVE AMOUNT OF DRUG 





FIGURE34c: COMPARISON OF CUMULATIVE AMOUNT OF DRUG 
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CHAPTERXI 
SUMMARY AND CONCLUSION 
  
1. In the present study an attempt was made to develop nanoparticles of 
felodipine in order to enhance its solubility  and dissolution rate by decreasing 
its particle size to nano level and to sustain its therapeutic activity  using 
Eudragit  L  and Eudragit S 100.  
2. IR spectroscopy studies confirmed that there was no interaction between drug 
and polymers. 
3. The felodipine loaded polymeric nanoparticles were successfully prepared by 
nanoprecipitation technique using Eudragit L100 and Eudragit S100 as 
polymers in the presence of stabilizers (Pluronic F 68 and Polyvinyl alcohol). 
4. The drug content analysis showed minimum variations suggesting uniform 
distribution of drug. 
5. The entrapment efficiency of all the formulations  increased with increasing 
the concentration of polymers and decreased with increasing concentration of 
stabilizers. 
6. Particle size analyzer used to explore the particle size of felodipine loaded 
polymeric  nanoparticles  showed  a  suitable  particle   size  in the range of  
192.4 nm -302.4nm. 
7. The polydispersity index of polymeric nanoparticle formulation was less than 
0.3, which indicated a relative homogenous dispersion. 
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8. Zeta potential of felodipine loaded polymeric nanoparticles showed a negative 
surface charge due to the presence of terminal carboxylic groups in the 
polymers. 
9. The in vitro drug release studies displayed a  biphasic drug release pattern 
with a burst release within 2 hours followed by sustained release for 12 hours. 
10. In vitro drug release kinetics showed sustained release and non fickian 
diffusion mechanism.  
11. On the basis of release data and kinetic analysis F7 showed a good sustained 
release profile with maximum entrapment efficiency. 
12. The solubility of felodipine loaded polymeric nanoparticles increased  to ten 
folds when compared to pure drug solution. 
13. SEM analysis of the polymeric nanoparticles showed the spherical shape of 
the nanoparticles. 
14. The  results  of  ex vivo  intestinal  permeability  studies  showed  an  increase 
in  the permeation  of  felodipine  loaded  polymeric  nanoparticles  across  
small intestinal  segments  when  compared  to  pure  drug  solution. 
 
Conclusion 
Hence, it was concluded that the polymeric nanoparticles prepared by 
nanoprecipitation is one of the useful method for the successful incorporation of 
felodipine with high entrapment efficiency. The solubility and ex vivo  intestinal  
permeability  studies suggested that the nanoparticle formulations can improve the 
bioavailability of felodipine by improving its solubility. Furthermore, it could be 
presumed that if the nanometer range of particles were obtained, the bioavailability 
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might be increased. Hence, we can conclude that polymeric nanoparticles enhanced 
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